1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy

ABSTRACT

The invention concerns 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein: R 1  and R 2 , identical or different, represent a branched or linear C 1 -C 7  alkyl or alkenyl radical, a C 1 -C 6  alkyl radical substituted by groups such as trifluoromethyl, C 5 -C 6  cycloalkyl, nitrile, C 1 -C 4  alkoxycarbonylvinyl, hydroxycarbonylvinyl, C 1 -C 4  alkoxycarbonyl, carboxylate, benzyloxy or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C 1 -C 4  alkoyl, C 1 -C 4  alkoxy, nitro, halogen, trifluoromethyl); YR 3  represents oxygen or NR 3  for which R 3  represents hydrogen, a linear or branched C 1 -C 7  alkyl or alkenyl radical, a C 1 -C 6  alkyl radical substituted by groups such as trifluoromethyl or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C 1 -C 4  alkoyl, C 1 -C 4  alkoxy, nitro, halogen, trifluoromethyl); Z represents an oxygen atom or a carbon atom capable of being bound to the ortho, meta or para positions of the phenyl group of formula I; n can be 0 to 5 when Z=C or 2 to 4 when Z=O; X represents oxygen or sulphur; R 4 , R 5 , R 6 , R 7  and R 8  represent hydrogen or fluorine; R 9 , R 10  and R 11  represent hydrogen or a linear or branched C 1 -C 5  alkyl group as well as the pharmaceutically acceptable base addition salts, and the various enantiomers of compounds having asymmetric carbons, and their mixtures in all proportions including in particular the racemic mixtures.

The present invention has as an aim new derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine functionalized at 2, 4 and 6 which activate PPAR alpha and/or gamma receptors, their preparation and their application in human therapeutics.

Metabolic syndrome is the result of a peripheral resistance to increased insulin and is characterized by hyperinsulinemia, intolerance to glucose, change in lipid metabolism and arterial hypertension (Grundy, S. M.: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 1999, 83, 25F-29F). Obesity is often associated with these metabolic disorders, and the conjunction of these multiple risk factors favors the development of the atheromatosis at the origin of arterial thrombosis, today the number one cause of mortality in industrialized areas. Peroxisome proliferator-activated receptors (PPAR) belong to the superfamily of transcription factor nuclear receptors. After activation, they form heterodimers with 9-cis retinoic acid receptor (RXR); this complex (PPAR-RXR) is linked specifically with DNA sequences located in the regulatory regions of genes implicated in the metabolism of lipids and carbohydrates (Pineda Torra, I., Gervois, P. and Staels, B.: Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol. 1999, 10, 151-159. Vamecq, J. and Latruffe, N.: Medical significance of peroxisome proliferator-activated receptors. Lancet 1999, 354, 141-148.). PPAR activation, on the one hand, restores certain altered metabolic pathways that predispose to atherosclerosis, and on the other reduces the inflammatory events which favor atheroma plaque development and rupture.

The compounds of the present invention are characterized by their original structure, their affinity with respect to alpha and/or gamma PPAR receptors and their pharmacological profile.

The compounds of the invention correspond to the general formula I.

in which

-   -   R₁ and R₂ can be identical or different and represent an alkyl         or alkenyl radical, linear or branched, at C₁-C₇, an alkyl         radical at C₁-C₆ substituted by groups such as trifluoromethyl,         cycloalkyl at C₅-C₆, nitrile, alkoxycarbonylvinyl at C₁-C₄,         hydroxycarbonylvinyl, alkoxycarbonyl at C₁-C₄, carboxylate,         benzyloxy or phenyl (for which the core phenyl is possibly         substituted by one or more groups such as alkyl at C₁-C₄, alkoxy         at C₁-C₄, nitro, halogen or trifluoromethyl),     -   YR₃ represents oxygen or NR₃ in which R₃ represents hydrogen, an         alkyl or alkenyl radical, linear or branched at C₁-C₇, an alkyl         radical at C₁-C₆ substituted by groups such as trifluoromethyl         or phenyl (for which the core phenyl is possibly substituted by         one or more groups such as alkyl at C₁-C₄, alkoxy at C₁-C₄,         nitro, halogen or trifluoromethyl),     -   Z represents an oxygen atom or a carbon atom which can be bound         in ortho, meta or para position on the phenyl group of formula         I,     -   n can range from 0 to 5 when Z=C or from 2 to 4 when Z=O,     -   X represents oxygen or sulfur,     -   R₄, R₅, R₆, R₇ and R₈ represent hydrogen or fluorine,     -   R₉, R₁₀ and R₁₁ represent hydrogen or an alkyl group, linear or         branched, at C₁-C₅,         as well as additive salts with pharmaceutically acceptable bases         and the various enantiomers of compounds having asymmetrical         carbons, as well as their mixtures in all proportions, including         racemic mixtures in particular.

The invention relates, in particular, to the compounds of formula I in which:

-   -   R₁ and R₂ represent, independently one from the other, an alkyl         or alkenyl radical, linear or branched, at C₁-C₇, an alkyl         radical at C₁-C₆ substituted by groups such as trifluoromethyl,         cycloalkyl at C₆, nitrile, or phenyl (for which the core phenyl         is possibly substituted by one or more groups such as alkyl at         C₁-C₄, alkoxy at C₁-C₄, nitro, halogen or trifluoromethyl),     -   YR₃ represents oxygen or NR₃ in which R₃ represents hydrogen, an         alkyl or alkenyl radical, linear or branched, at C₁-C₇, an alkyl         radical at C₁-C₆ substituted by groups such as trifluoromethyl         or phenyl,     -   Z represents an oxygen atom or a carbon atom which can be bound         in ortho, meta or para position on the phenyl group of formula I     -   n can range from 0 to 5 when Z=C or from 2 to 4 when Z=O,     -   X represents oxygen or sulfur,     -   R₄, R₅, R₆, R₇ and R₈ represent hydrogen or fluorine,     -   R₉, R₁₀ and R₁₁ represent hydrogen or an alkyl group, linear or         branched, at C₁-C₅.

The invention relates, more particularly, to the compounds of formula I in which:

-   -   R₁ and R₂ represent independently one from the other, an alkyl         or alkenyl radical, linear or branched, at C₁-C₇, an alkyl         radical at C₁-C₆ substituted by groups such as trifluoromethyl         or nitrile,     -   YR₃ represents oxygen or NR₃ in which R₃ represents hydrogen or         a linear or branched alkyl radical at C₁-C₇,     -   Z represents a carbon atom which can be bound in ortho, meta or         para position on the phenyl group of formula I,     -   n can range from 0 to 5,     -   X represents oxygen or sulfur,     -   R₄, R₅, R₆, R₇ and R₈ represent hydrogen or fluorine,     -   R₉, R₁₀ and R₁₁ represents hydrogen or a linear or branched         alkyl group at C₁-C₅, in particular R₉ and R₁₀ represent a         methyl group and R₁₁ hydrogen or an ethyl group.

The invention relates still more particularly to the derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine of formula I in which:

-   -   R₁ and R₂ represent independently one from the other, an alkyl         or alkenyl radical, linear or branched, at C₁-C₇, possibly         substituted at the end of the chain by a trifluoromethyl group,     -   YR₃ represents oxygen or NR₃ in which R₃ represents hydrogen or         a linear or branched alkyl radical at C₁-C₇,     -   Z represents a carbon atom which can be bound in meta or para         position on the phenyl group of formula I,     -   n can range from 1 to 5,     -   X represents oxygen or sulfur,     -   R₄ to R₈ represent hydrogen,     -   R₉ and R₁₀ represent a methyl radical     -   R₁₁ represents hydrogen or an ethyl radical.

The invention encompasses salts of the compounds of general formula I with pharmaceutically acceptable bases, as well as the various enantiomers of compounds possessing asymmetrical carbons, as well as their mixtures in all proportions including racemic mixtures in particular.

Synthesis

The compounds of the present invention can be synthesized by using the synthetic pathways described below or by using synthesis methods known to those skilled in the art.

Method 1

The synthesis of compounds of general formula I is characterized (diagram 1) wherein a derivative of general formula II is condensed

in which R₁ and R₂ represent the groups as previously described in formula I with a derivative of general formula III

where YR₃, n, Z, X, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are such as described previously in formula I. This reaction can be carried out in the presence of a base such as triethylamine in n-butanol (when Y═N) or potassium carbonate in dimethylformamide (when YR₃═O);

Method 2

This synthesis method for compounds of general formula I for which Z=O (diagram 2) is characterized wherein:

1) a derivative of general formula II is condensed

in which R₁ and R₂ represent the groups as previously described in formula I with a derivative of general formula IV

in which R₃Y can be equal to NH or O and n is such as described previously in formula I. This reaction can be carried out in the absence of solvent without adding base (in the case where R₃Y═NH) or in the presence of a base such as K₂CO₃ (in the case where R₃Y═O).

2) the derivative obtained V is condensed

with a compound of general formula VI

where X, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are as described previously in formula I. This reaction can be carried out under conditions such as those of the Mitsunobu reaction in the presence of triphenylphosphine and diethylazodicarboxylate in THF.

Method 3

This synthesis method for compounds of general formula I for which Z=O (diagram 3) is characterized wherein:

1) the alcohol function of a derivative of general formula VII is protected

in which R₁, R₂ and n are as described previously in formula I by a protection group such as tert-butyldimethylsilane. This reaction can be carried out under conditions such as THF by using chlorotertbutyldimethylsilane and imidazole.

2) the nitrogen of compound VIII previously obtained is alkylated by a halogenated derivative R₃Hal in which the Hal group represents a halogen such as Cl, Br or I and R₃ is as described previously in formula I, under operating conditions such as NaH or tBuOK in DMF.

3) the compound IX thus obtained is deprotected under operating conditions such as tetrabutylammonium fluoride in THF.

4) the derivative obtained X is condensed

with a compound of general formula VI

where X, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are as described previously in formula I. This reaction can be carried out under conditions such as those of the is Mitsunobu reaction in the presence of triphenylphosphine and diethylazodicarboxylate in THF.

Method 4

This method is implemented when Y═N and Z=C and it is characterized (diagram 4) wherein:

1) a derivative of general formula II is condensed

in which R₁ and R₂ represent the groups as previously described in formula I with a derivative of general formula XI

in which n, R₃ R₄, R₅, R₆, R₇ and R₈ are as described previously in formula I and A can be hydrogen or a methyl group. This reaction can be carried out in the presence of a base such as triethylamine in n-butanol.

2) after demethylation (if A=Me, under conditions such as BBr₃ in dichloromethane), the phenol function of derivative XII is alkylated

by a halogenated derivative of general formula XIII (used as a solvent in the presence of a base such as potassium carbonate)

in which the Hal group represents a halogen such as Cl, Br or I, and R₉, R₁₀ and R₁₁ are as previously described in general formula I.

Method 5

This method is implemented when Y═N and Z=C and it is characterized (diagram 5) wherein:

1) a derivative of general formula XIV is alkylated

in which R₁, R₂, R₄, R₅, R₆, R₇, R₈ et n are as described previously in formula I with a derivative of formula R₃Hal in which the Hal group represents a halogen such as Cl, Br or I and R₃ is as described previously in formula I, under operating conditions such as NaH or tBuOK in DMF.

2) after demethylation under conditions such as BBr₃ in dichloromethane, the phenol function of the derivative XII thus obtained is alkylated

by a halogenated derivative of general formula XIII (used as a solvent in the presence of a base such as potassium carbonate)

in which the Hal group represents a halogen such as Cl, Br or I, and R₉, R₁₀ and R₁₁ are as previously described in general formula I.

Method 6

This method is characterized (diagram 6) wherein:

1) a derivative of general formula XIV is placed

in which R₁═(CH₂)₂CN and R₂, R₃, n, Z, X, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are as described previously in formula I or R₂═(CH₂)₂CN and R₁, R₃, n, Z, X, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are as described previously in formula I under operating conditions such as in the presence of a base NaH in DMF.

2) the nitrogen of the triazine of derivative XIVa or XIVb thus obtained is then alkylated

by a halogenated derivative of general formula R₁Hal in the case of the intermediate XIVa and of general formula R₂Hal in the case of the intermediate XIVb in which the Hal group represents a halogen such as Cl, Br or I and R₁ and R₂ are as described previously in formula I, under operating conditions such as NaH or tBuOK in DMF.

If desired, the intermediate and final compounds can be purified according to one or more purification methods chosen among extraction, filtration, silica gel chromatography, normal or reverse phase preparative HPLC and crystallization.

The raw materials used in the methods described previously are commercially available or easily accessible to those skilled in the art according to methods described in the literature.

The following examples illustrate the invention without limiting its scope.

Elementary analyses and IR and NMR spectra confirm the compounds' structures.

Intermediates Intermediate 1: a) 6-Bromo-2H-[1,2,4]triazine-3,5-dione (1a)

2H-[1,2,4]triazin-3,5-dione (50 g, 442 mmol) is placed in the presence of 60 ml of bromine in 800 ml of water at 60° C. for 10 h. The reaction medium is then slowly added to an ammonia solution until pH=5. It is then extracted in ethyl acetate and the organic phases are dried on MgSO₄. After filtration and dry concentration, 1a is isolated in the form of a white solid (79.2 g, yield=93%). TLC silica gel 60 F 254 Merck, CH₂Cl₂:MeOH 90:10, Rf=0.32.

b) 6-Bromo-2,4-dimethyl-2H-[1,2,4]triazine-3,5-dione (1b)

11.8 g (295 mmol) of NaH (60% in paraffin) is placed in suspension at 0° C. in 250 ml of DMF under nitrogen. 25.80 g (135 mmol) of intermediate 1a diluted in 150 ml of DMF is added drop by drop. This solution is then placed at ambient temperature and 18.4 ml (296 mmol) of methyl iodide is added dropwise. After a night of stirring and after dry concentration of the reaction medium, the residue obtained is taken up in water and extracted with ethyl acetate. The organic phases are washed with brine, dried on magnesium sulfate then dry concentrated. The residue obtained, taken up in ether, crystallizes and a first crystal fraction is isolated. The filtrate is dry concentrated the purified by plash chromatograph on silica (heptane:AcOEt 50:50). 24 g of intermediate 1b are thus isolated (81% yield) TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 80:20, Rf=0.59.

c) Intermediates (1c)-(1g)

The synthesis of intermediates 1c-1g is carried out starting from 1a according to the procedure described for the synthesis of 1b by using various alkylation agents RX.

TABLE 1 intermediates 1c-1g Intermediates RX Yield TLC State 1c-1g

80% PE:AcOEt 80:20Rf = 0.42 oil 1c: 6-Bromo-2,4-dibutyl-2H-[1,2,4]triazine-3,5-dione

95% PE:AcOEt 80:20Rf = 0.75 solid 1d: 6-Bromo-2,4-bis-(4,4,4-trifluoro-butyl)-2H-[1,2,4]-triazine-3,5-dione

95% PE:AcOEt 90:10Rf = 0.81 oil 1e: 6-Bromo-2,4-diheptyl-2H-[1,2,4]triazine-3,5-dione

92% PE:AcOEt 90:10Rf = 0.82 oil 1f: 6-Bromo-2,4-bis-(3-cyclohexyl-propyl)-2H-[1,2,4]triazine-3,5-dione

98% PE:AcOEt 70:30Rf = 0.62 oil 1g: 2,4-Bis-benzyloxymethyl-6-bromo-2H-[1,2,4]triazine-3,5-dione TLC: silica gel 60 F 254 Merck, PE = petroleum ether

Intermediate 2: a) 6-Bromo-4-methyl-2H-[1,2,4]triazine-3,5-dione (2a)

20.3 g (105.7 mmol) of triazine 1a are placed in 150 ml of acetic anhydride at reflux for 4.5 h. After dry concentration of the reaction medium, a precipitate is isolated then recrystallized in ether: 24.3 g of crystals are isolated (yield=98%). 4.5 g (114.2 mmol) of NaH (60% in paraffin) are placed in 50 ml of DMF under nitrogen. A solution of 24.3 g (103.8 mmol) of crystals isolated previously in 150 ml of DMF is added dropwise. The reaction medium is stirred for 45 nm at ambient temperature and then 7 ml (114.2 mmol) of methyl iodide are added; stirring is then continued for 21 h at ambient temperature. After dry concentration, the residue obtained is taken up in H₂O and extracted with ethyl acetate. After drying on MgSO₄, the organic phases are evaporated and the clear oil obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 90:10). 22.9 g of crystals (yield=89%) are isolated and are placed in 300 ml of ethanol in the presence of 0.6 g of p-toluene sulfonic acid. This mixture is heated at reflux for 4.5 h and then dry concentrated. The residue is taken up in H₂O and extracted with ethyl acetate. After drying and evaporation of the organic phases, 17 g of intermediate 2a is isolated in the form of a solid (yield=89%). TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 90:10, Rf=0.29.

b) Intermediates (2b)-(2f)

The synthesis of intermediates 2b-2f is carried out starting from 1a according to the procedure described for the synthesis of 2a by using various alkylation agents RX.

TABLE 2 intermediates 2b-2f Total Intermediates RX yield TLC State 2b-2f

73% PE:AcOEt 80:20Rf = 0.28 solid 2b: 6-Bromo-4-butyl-2H-[1,2,4]triazine-3,5-dione

60% PE:AcOEt 80:20Rf = 0.26 solid 2c: 6-Bromo-4-(3-methyl-but-2-enyl)-2H-[1,2,4]triazine-3,5-dione

76% CH₂Cl₂:AcOEt90:10Rf = 0.45 solid 2d: 6-Bromo-4-(4,4,4′-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione

84% PE:AcOEt 70:30Rf = 0.73 solid 2e: 6-Bromo-4-heptyl-2H-[1,2,4]triazine-3,5-dione

82% PE:AcOEt 70:30Rf = 0.25 solid 2f: 4-Benzyl-6-bromo-2H-[1,2,4]triazine-3,5-dione TLC: silica gel 60 F 254 Merck, PE = petroleum ether

Intermediate 3: a) 3-(6-Bromo-4-methyl-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-propionitrile (3a)

2.4 g (11.6 mmol) of triazine 2a and 7 ml (106 mmol) of acrylonitrile are placed in 24 ml of a solution of pyridine and water (1:1) at reflux for 3 h. After concentration the reaction medium is extracted by AcOEt, and after drying on MgSO₄ the organic phases are dry concentrated. 2.8 g of solid 3a are isolated and then washed with ether (yield=93%). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.18.

b) Intermediates 3b and 3c

The synthesis of intermediates 3b and 3c is carried out starting from intermediates 2d and 2e, respectively, following the procedure described for the synthesis of 3a.

TABLE 3 intermediates 3b and 3c Starting molecule Yield TLC State Intermediates 3b-3c 2d 91% PE:AcOEt 70:30 solid 3b: 3-[6-Bromo-3,5-dioxo- Rf = 0.34 4-(4,4,4-trifluoro-butyl)- 4,5-dihydro-3H- [1,2,4]triazin-2-yl]- propionitrile 2e 95% CH₂Cl₂:AcOEt solid 3c: 3-(6-Bromo-4-heptyl- 70:30 3,5-dioxo-4,5-dihydro-3H- Rf = 0.51 [1,2,4]triazin-2-yl)- propionitrile TLC: silica gel 60 F 254 Merck, PE = petroleum ether

Intermediate 4: d) 6-Bromo-4-methyl-2-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione (4a)

0.85 g (21.3 mmol) of NaH (60% in paraffin) is placed in 10 ml of DMF under nitrogen. A solution of 4 g (19.4 mmol) of intermediate 2a in 40 ml of DMF is added dropwise. The reaction medium is stirred for 1 h at ambient temperature and then 5 g (21.3 mmol) of 1,1,1-trifluoro-4-iodo-butane are added; stirring is then continued for 3 h at ambient temperature. After dry concentration, the residue obtained is taken up in H₂O and extracted with ethyl acetate. After drying on MgSO₄, the organic phases are evaporated and the oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 80:20). 5.3 g of crystals corresponding to compound 4a are isolated (yield=87%). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.58.

d) 6-Bromo-2-heptyl-4-methyl-2H-[1,2,4]triazine-3,5-dione (4b)

The synthesis of intermediate 4b is carried out starting from 2a according to the procedure described for the synthesis of 4a by using 1-bromoheptane for the alkylation step (yield=91%). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.76.

Intermediate 5:

The synthesis of intermediates 5a-5d is carried out starting from intermediates 2b and 2c according to the procedure described for the synthesis of 4a by using various halogenated derivatives R₁X.

TABLE 4 intermediates 5a-5d Intermediates R₁X Yield TLC State 5a-5c —I 64% CH₂Cl₂:AcOEt solid 5a: 6-Bromo-4-butyl-2- 95:5 methyl-2H- Rf = 0.75 [1,2,4]triazine-3,5-dione

95% PE:AcOEt80:20Rf = 0.61 oil 5b: 6-Bromo-4-butyl-2-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione

72% PE:AcOEt 80:20Rf = 0.75 oil 5c: 6-Bromo-4-butyl-2-heptyl-2H-[1,2,4]triazine-3,5-dione

90% PE:AcOEt 80:20Rf = 0.58 oil 5d: 6-Bromo-4-(3-methyl-but-2-enyl)-2-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione TLC: silica gel 60 F 254 Merck, PE = petroleum ether

Intermediate 6:

The synthesis of intermediates 6a-6c is carried out starting from intermediate 2d according to the procedure described for the synthesis of 4a by using various halogenated derivatives RX.

TABLE 5 intermediates 6a-6c Intermediates RX Yield TLC State 6a-6b —I 91% PE:AcOEt 70:30 solid 6a: 6-Bromo-2-methyl-4- Rf = 0.61 (4,4,4-trifluoro- butyl)-2H- [1,2,4]triazine-3,5- dione

88% PE:AcOEt 60:40Rf = 0.53 oil 6b: 6-Bromo-2-heptyl-4-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione

80% PE:AcOEt 60:40Rf = 0.43 oil 6c: 6-Bromo-2-(3-cyclohexyl-propyl)-4-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione TLC: silica gel 60 F 254 Merck, PE = petroleum ether

Intermediate 7:

The synthesis of intermediates 7a-7d is carried out starting from intermediate 2e according to the procedure described for the synthesis of 4a by using various halogenated derivatives RX.

TABLE 6 intermediates 7a-7d Intermediates RX Yield TLC State 7a-7d —I 92% CH₂Cl₂:MeOH oil 7a: 6-Bromo-4-heptyl-2- 95-5 methyl-2H- Rf = 0.65 [1,2,4]triazine-3,5- dione

98% PE:AcOEt 70:30Rf = 0.81 oil 7b: 6-Bromo-4-heptyl-2-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione

80% PE:AcOEt 80:20Rf = 0.60 oil 7c: 2-Benzyl-6-bromo-4-heptyl-2H-[1,2,4]triazine-3,5-dione

78% PE:AcOEt 80:20Rf = 0.59 oil 7d: 6-Bromo-2-cyclohexylmethyl-4-heptyl-2H-[1,2,4]triazine-3,5-dione TLC: silica gel 60 F 254 Merck, PE = petroleum ether

Intermediate 8:

The synthesis of intermediates 8a-8b is carried out starting from intermediate 2f according to the procedure described for the synthesis of 4a by using various halogenated derivatives RX.

TABLE 7 intermediates 8a-8b Intermediates RX Yield TLC State 8a-8b

93% PE:AcOEt 80:20Rf = 0.46 oil 8a: 4-Benzyl-6-bromo-2-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione

98% PE:AcOEt 80:20Rf = 0.66 oil 8b: 4-Benzyl-6-bromo-2-heptyl-2H-[1,2,4]triazine-3,5-dione TLC: silica gel 60 F 254 Merck, PE = petroleum ether

Intermediate 9: a) 6-(2-Hydroxy-ethylamino)-2,4-bis-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione (9a)

3 g (7.3 mmol) of triazine 1d are placed in 1.3 ml of ethanolamine at 130° C. for 5 h. After cooling, 50 ml of water are added to the reaction medium which is then extracted with AcOEt. After drying on MgSO₄, the organic phases are dry concentrated and the residue obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 70:30). 1.9 g of oil corresponding to intermediate 9a is thus isolated (66% yield). TLC silica gel 60 F 254. Merck, petroleum ether:AcOEt 70:30, Rf=0.28.

b) Intermediates 9b-9l

The synthesis of intermediates 9b-9l is carried out from the starting compounds listed in table 8 following the procedure described for the synthesis of 9a.

TABLE 8 intermediates 9b-9l Starting Amino molecule alcohol Yield TLC State Intermediates 9b-9k 4b Ethanol- 77% CH₂Cl_(2:)AcOEt solid 9b: 2-Heptyl-6-(2- amine 60:40 hydroxy-ethylamino)- Rf = 0.28 4-methyl-2H- [1,2,4]triazine-3,5-dione 1e Ethanol- 67% PE:AcOEt 70:30 oil 9c: 2,4-Diheptyl-6- amine Rf = 0.56 (2-hydroxy ethylamino)-2H- [1,2,4]triazine-3,5-dione 1f Ethanol- 56% PE:AcOEt 80:20 oil 9d: 2,4-Bis-(3- amine Rf = 0.18 cyclohexyl-propyl)-6- (2-hydroxy-ethyl-amino)-2H- [1,2,4]triazine-3,5-dione 1b Amino- 18% AcOEt oil 9e: 6-(3-Hydroxy- propanol Rf = 0.42 propyl-amino)-2,4- dimethyl-2H- [1,2,4]triazine-3,5-dione 4a Amino- 44% PE:AcOEt 70:30 solid 9f: 6-(3-Hydroxy- propanol Rf = 0.13 propylamino)-4- methyl-2-(4,4,4- trifluoro-butyl)-2H- [1,2,4]triazine-3,5-dione 4b Amino- 67% CH₂Cl₂:AcOEt solid 9g: 2-Heptyl-6-(3- propanol 60:40 hydroxy-propylamino)- Rf = 0.32 4-methyl-2H- [1,2,4]triazine-3,5-dione 6a Amino- 45% PE:AcOEt 80:20 solid 9h: 6-(3-Hydroxy- propanol Rf = 0.05 propyl-amino)-2- methyl-4-(4,4,4- trifluoro-butyl)-2H- [1,2,4]triazine-3,5- dione 7a Amino- 34% CH₂Cl₂:MeOH solid 9i: 4-Heptyl-6-(3- propanol 90:10 hydroxy-propylamino)- Rf = 0.47 2-methyl-2H- [1,2,4]triazine-3,5-dione 7b Amino- 64% PE:AcOEt 70:30 solid 9j: 4-Heptyl-6-(3- propanol Rf = 0.30 hydroxy-propylamino)- 2-(4,4,4-trifluoro- butyl)-2H- [1,2,4]triazine-3,5-dione 1b Amino- 50% AcOEt solid 9k: 6-(4-Hydroxy- butanol Rf = 0.35 butyl-amino)-2,4- dimethyl-2H- [1,2,4]triazine-3,5-dione 7a Amino- 21% CH₂Cl₂:MeOH solid 9l: 4-Heptyl-6-(4- butanol 90:10 hydroxy-butylamino)- Rf = 0.45 2-methyl-2H- [1,2,4]triazine-3,5-dione TLC: silica gel 60 F 254 Merck, PE = petroleum ether

c) 2-heptyl-6-[(3-hydroxy-propyl)-(4,4,4-trifluoro-butyl)-amino]-4-methyl-2H-[1,2,4]triazine-3,5-dione (9m)

7.3 g (24.2 mmol) of triazine 9g are placed in the presence of tert-butyl-chloro-dimethyl-silane (4 g, 26.5 mmol) in 50 ml of dichloromethane at ambient temperature overnight. The reaction medium is then washed with water followed with brine. After drying on MgSO₄, the organic phase is dry concentrated and the residue obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 95:5). 10 g of oil are isolated (quantitative yield). 4.1 g (10 mmol) of this compound are placed in 40 ml of DMF at 0° C. under nitrogen and then 0.4 g (10 mmol) of NaH (60% in paraffin) is added by fractions; this mixture is then stirred for 10 nm. 2.4 g (10 mmol) of 1,1,1-trifluoro-4-iodo-butane are added and the solution is stirred at ambient temperature for 3 h. 0.5 equivalent of NaH as well as 1,1,1-trifluoro-4-iodo-butane are again added and stirring is continued for 2 h. After dry concentration, the residue is taken up in H₂O then extracted with AcOEt. After drying on MgSO₄, the organic phases are dry concentrated and the oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 90:10). 2 g of compound (yield=40%) are isolated and then diluted in 30 ml of THF; 7.4 ml of a tetrabutylammonium fluoride solution (1 M in THF) is then added dropwise. This mixture is stirred for 2 h at ambient temperature and then 50 ml of water are added and the medium is extracted with AcOEt. After drying on MgSO₄, the organic phases are dry concentrated and the oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 70:30). 1.5 g of triazine 9m is this isolated in the form of oil (quantitative yield). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 90:10, Rf=0.38.

d) Intermediates 9n-9o

The synthesis of intermediates 9n and 9o is carried out starting from intermediates 9e and 9k, respectively, following the procedure described for the synthesis of 9m using bromoheptane.

TABLE 9 intermediates 9n-9o Starting molecule Yield TLC State Intermediates 9n-9o 9e 59% heptane:AcOEt oil 9n: 6-[Heptyl-(3-hydroxy- 50:50 propyl)-amino]-2,4-dimethyl- Rf = 0.16 2H-[1,2,4]triazine-3,5- dione 9k 59% heptane:AcOEt oil 9o: 6-[Heptyl-(4-hydroxy- 50:50 butyl)-amino]-2,4-dimethyl- Rf = 0.24 2H-[1,2,4]triazine-3,5-dione TLC: silica gel 60 F 254 Merck, PE = petroleum ether

e) 2-heptyl-6-(2-hydroxy-ethoxy)-4-methyl-2H-[1,2,4]triazine-3,5-dione (9p)

1.5 g (4.9 mmol) of triazine 4b and 0.8 g (5.8 mmol) of K₂CO₃ are placed in 1.5 ml of ethyleneglycol at 130° C. for 0.5 h. 50 ml of water are added to the reaction medium which is then extracted with AcOEt. After drying on MgSO₄, the organic phases are dry concentrated and the residue obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 70:30). 0.5 g of oil corresponding to intermediate 9p is thus isolated (39% yield). TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.08.

f) Intermediates 9q-9s

The synthesis of intermediates 9q-9s is carried out from starting compounds 4b and 1d according to the procedure described for the synthesis of 9p using various diols.

TABLE 10 intermediates 9q-9s Starting Intermediates molecule Diol Yield TLC State 9q-9s 4b

78% AcOEtRf = 0.41 oil 9q: 2-Heptyl-6-(3-hydroxy-propoxy)-4-methyl-2H-[1,2,4]triazine-3,5-dione 1d

67% AcOEtRf = 0.44 oil 9r: 6-(3-Hydroxy-propoxy)-2,4-bis-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione 4b

70% AcOEtRf = 0.31 oil 9s: 2-Heptyl-6-(4-hydroxy-butoxy)-4-methyl-2H-[1,2,4]triazine-3,5-dione TLC: silica gel 60 F 254 Merck

Intermediate 10: a) 3-(2-Hydroxy-ethyl)-phenol (10a)

11.3 g of (3-hydroxy-phenyl)-acetic acid (74.2 mmol) are placed in 100 ml of THF at 0° C. under nitrogen. 100 ml of a solution of LiAlH₄ (1 M in THF) is added dropwise at this temperature. The mixture is then placed at 60° C. for 2 h. It is then neutralized slowly with a 6 N HCl solution then extracted with diethyl ether. The organic phases are washed with water, dried on MgSO₄, then dry concentrated. The residue obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 70:30). 9 g of oil corresponding to intermediate 10a are thus isolated (88% yield). TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 70:30, Rf=0.18.

b) Ethyl 2-(3-hydroxy-phenoxy)-2-methyl-propionate (10b)

15 g of resorcinol (136 mmol) are added to 120 ml of a solution of sodium (6.3 g, 274 mmol) in ethanol. The mixture is placed at reflux for 1 h then a solution of ethyl bromoisobutyrate (13.2 ml, 90 mmol) in 30 ml of ethanol is added dropwise. Heating is maintained for 3 h then the reaction medium is dry concentrated. The residue obtained is taken up in a solution of water and acetic acid then extracted with AcOEt. The organic phases are washed with water, dried on MgSO₄, then dry concentrated. The residue obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 90:10). 14.4 g of oil corresponding to intermediate 10b are thus isolated (72% yield). TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 70:30, Rf=0.66.

c) Ethyl 2-(4-hydroxy-phenoxy)-2-methyl-propionate (10c)

11 g of hydroquinone (100 mmol) in 100 ml of DMF is placed at 80° C. for 2 h. This mixture is cooled at ambient temperature then a solution of ethyl bromoisobutyrate (14.7 ml, 100 mmol) in 30 ml of DMF is added dropwise. The mixture is stirred for 3 h then the reaction medium is dry concentrated. The residue obtained is taken up in a 1 N HCl solution then extracted with AcOEt. The organic phases are washed with water, dried on MgSO₄, then dry concentrated. The residue obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 80:20). 9 g of oil corresponding to intermediate 10c are thus isolated (40% yield). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.50.

d) Ethyl 2-(3-bromo-phenoxy)-2-methyl-propionate (10d)

25 g (144.5 mmol) of 3-bromophenol are placed in the presence of K₂CO₃ (21 g, 152 mmol) in 75 ml of ethyl 2-bromoisobutyrate and heated to reflux for 7 h. After elimination of K₂CO₃ by filtration, the reaction medium is dry concentrated. After purification by flash chromatography on silica (petroleum ether:AcOEt 90:10), 37 g of intermediate 10d are collected in the form of clear oil (yield=89%). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 90:10, Rf=0.40.

d) Intermediates 10e-10j

The synthesis of intermediates 10e-10j is carried out from the variously substituted phenols listed in table 8 following the procedure described for the synthesis of 10d.

TABLE 11 intermediates 10e-10j Starting Intermediates phenol Yield TLC State 10e-10j

98% PE:AcOEt 90:10Rf = 0.52 oil 10e: Ethyl 2-(4-bromo-phenoxy)-2-methyl-propionate

52% CH₂Cl₂:AcOEt 80:20Rf = 0.36 oil 10f: Ethyl 2-(4-hydroxymethyl-phenoxy)-2-methyl-propionate

19% CH₂Cl₂:AcOEt 90:10Rf = 0.50 oil 10g: Ethyl 2-[2-(2-hydroxy-ethyl)-phenoxy]-2-methyl-propionate 10a 9% CH₂Cl₂: oil 10h: Ethyl 2-[3-(2- AcOEt 70:30 hydroxy-ethyl)-phe- Rf = 0.68 noxy]-2-methyl- propionate

61% CH₂Cl₂:AcOEt 90:10Rf = 0.21 oil 10j: Ethyl 2-[4-(2-hydroxy-ethyl)-phe-noxy]-2-methyl-propionate TLC: silica gel 60 F 254 Merck, PE = petroleum ether

Intermediate 11: a) Ethyl 2-(3-bromo-phenylsulfanyl)-2-methyl-propionate (11a)

10 g (52.9 mmol) of 3-bromothiophenol are placed in the presence of 9.4 ml (63.5 mmol) of ethyl bromoisobutyrate and 8 g (57.9 mmol) of K₂CO₃ in 100 ml of EtOH. This mixture is stirred at reflux for 4 h and then dry concentrated. The residue is taken up in water. After extraction in AcOEt and then drying on MgSO₄, the organic phases are dry concentrated. The oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 90:10) and 11a is isolated in the form of clear oil (16.8 g, quantitative yield). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 90:10, Rf=0.72.

c) Intermediates 11b-11e

The synthesis of intermediates 11b-11e is carried out starting from variously substituted thiophenols (G) listed in table 12 following the procedure described for the synthesis of 11a using ethyl or tert-butyl bromoisobutyrate.

TABLE 12 intermediates 11b-11e Starting thiophenol

Yield TLC State Intermediates 11b-11e

ethylbromoisobutyrate 87% PE:AcOEt90:10Rf = 0.70 oil 11b: Ethyl 2-(4-bromo-phenylsulfanyl)-2-methyl-propionate

ethylbromoisobutyrate 74% Heptane:AcOEt80:20Rf = 0.50 oil 11c: Ethyl 2-(3-hydroxy-phenylsul-fanyl)-2-methyl-propionate

ethylbromoisobutyrate 64% Heptane:AcOEt80:20Rf = 0.20 oil 11d: Ethyl 2-(4-hydroxy-phenylsul-fanyl)-2-methyl-propionate

tert-butylbromoisobutyrate 98% PE:AcOEt90:10Rf = 0.70 solid 11e: Tert-butyl-2-(4-bromo-phenyl-sulfanyl)-2-methyl-propionate TLC: silica gel 60 F 254 Merck, PE = petroleum ether

Intermediate 12: a) Ethyl 2-[3-(3-hydroxy-propyl)-phenoxy]-2-methyl-propionate (12a)

10d (50 g, 175 mmol) is placed in the presence of 2-propynol (12 ml, 210 mmol) in 400 ml of diisopropylamine, under nitrogen. Pd(PPh₃)₂Cl₂ (3.5 g) and CuI (500 mg) are added and the reaction medium is stirred at reflux for 5 h. The precipitate formed in the course of the reaction is filtered on celite and the reaction medium is dry concentrated. The oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 80:20). It is then placed in a solution of 250 ml of THF and 150 ml of EtOH in the presence of Pd/C under hydrogen at 6 bar. This mixture is stirred for 24 h. at ambient temperature. After filtration on celite, the reaction medium is dry concentrated and 12a is isolated in the form of a clear oil (32 g, yield=69%). TLC silica gel 60 F 254 Merck, heptane:AcOEt 80:20, Rf=0.56.

b) Intermediates 12b-12e

The synthesis of intermediates 12b-12e is carried out from the starting bromine compounds listed in table 13 following the procedure described for the synthesis of 12a using various alkynols. Note: in the case of a sulfur derivative, a Wilkinson catalyst is used for the hydrogenation step

TABLE 13 intermediates 12b-12e Starting molecule alkynol Yield TLC State Intermediates 12b-12d 10d

76% Heptane:AcOEt60-40Rf = 0.37 oil 12b: Ethyl 2-[3-(5-hydroxy-pentyl)-phenoxy]-2-methyl-propionate 10e

5% Heptane:AcOEt60-40Rf = 0.33 oil 12c: Ethyl 2-[4-(3-hydroxy-propyl)-phenoxy]-2-methyl-propionate 10e

55% PE:AcOEt80:20Rf = 0.14 oil 12d: Ethyl 2-[4-(4-hydroxy-butyl)-phenoxy]-2-methyl-propionate 11a

73% PE:AcOEt70:30Rf = 0.26 oil 12e: Ethyl 2-[3-(3-hydroxy-propyl)-phenylsulfanyl]-2-methyl-propionate TLC: silica gel 60 F 254 Merck, PE = petroleum ether

Intermediate 13: a) Ethyl 2-[4-(2-amino-ethyl)-phenoxy]-2-methyl-propionate (13a)

10.1 g (73.6 mmol) of tyramine is placed in the presence of sodium bicarbonate (6.1 g, 72.6 mmol) in a mixture of 100 ml of water and 50 ml of acetone at 0° C. 11.6 ml (81.2 mmol) of benzyl chloroformate is added dropwise at this temperature then the reaction medium is stirred 4 h at ambient temperature. After dry concentration, the residue obtained is taken up in water then extracted with AcOEt. After drying on MgSO₄, the organic phases are dry concentrated and the solid obtained is recrystallized in diethyl ether: 17.2 g of solid is thus obtained (86% yield). They are then placed in 37 ml of ethyl bromoisobutyrate in the presence of 8.8 g (63.7 mmol) of potassium carbonate at 130° C. for 5 h. After filtration, the reaction medium is dry concentrated and the residue obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 70:30). 22.7 g of clear oil are obtained (yield=93%). This oil is then placed in 200 ml of EtOH in the presence of palladium on carbon under, hydrogen at 3 bar and then this solution is stirred for 3 h at ambient temperature. After filtration on celite, the reaction medium is dry concentrated and 14.7 g of intermediate 13a is thus isolated in the form of an oil (quantitative yield). TLC silica gel 60 F 254 Merck, CH₂Cl₂:MeOH 90:10, Rf=0.11.

b) Ethyl 2-[3-(2-amino-ethyl)-phenoxy]-2-methyl-propionate (13b)

10d (14 g, 49 mmol) is placed in the presence of N-vinylphthalimide (11 g, 63 mmol) and 27 ml (194 mmol) of triethylamine in 160 ml of DMF. Pd(OAc)₂ (0.3 g) and P(oTol)₃ (0.4 g) are added and the reaction medium is stirred for 10 h at 110° C. The reaction medium is dry concentrated and the residue obtained is taken up in water and extracted with AcOEt. After drying on MgSO₄, the organic phases are dry concentrated and the oil isolated is purified by flash chromatography on silica (heptane:AcOEt 90:10). 11.5 g of oil is obtained (62% yield) then placed in a solution of 70 ml of THF and 70 ml of EtOH in the presence of Pd/C under hydrogen at 6 bar. This mixture is stirred for 72 h at ambient temperature. After filtration on celite, the reaction medium is dry concentrated and the residue obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 80:20). 10.9 g of clear oil are obtained (yield=94%). This oil is then placed in 140 ml of EtOH in the presence of 3.5 ml of hydrazine hydrate then this solution is heated at reflux for 4 h. After filtration of the insolubles, the reaction medium is dry concentrated and then the residue obtained is purified by flash chromatography on silica (CH₂Cl₂:MeOH:NH₄OH 90:9:1). 5.7 g of intermediate 13b are thus isolated in the form of an oil (yield=80%). TLC silica gel 60 F 254 Merck, CH₂Cl₂:MeOH:NH₄OH 90:9:1, Rf=0.28.

c) Intermediates 13c-13i

The synthesis of intermediates 13c-13i is carried out from the starting bromine compounds listed in table 14 following the procedure described for the synthesis of 13b using variously N-alkylated phthalimides. (Note: in the case of a sulfur derivative, a Wilkinson catalyst is used for the hydrogenation step

TABLE 14 intermediates 13b-13i Starting N-substituted Total TLC molecule phthalimide Yield Form State Intermediates 13c-13h 10d N- 80% CH₂Cl₂:MeOH oil 13c: Ethyl 2-[3-(3- allylphthalimide 90:10 amino-propyl)-phenoxy]- Rf = 0.12 2-methyl- propionate 11a N- 66% CH₂Cl₂:MeOH:NH₄OH oil 13d: Ethyl 2-[3-(2- vinylphthalimide 90:9:1 amino-ethyl)-phenyl- Rf = 0.20 sulfanyl]-2-methyl- propionate 11a N- 70% CH₂Cl₂:MeOH:NH₄OH oil 13e: Ethyl 2-[3-(3- allylphthalimide 90:9:1 amino-propyl)- Rf = 0.30 phenylsulfanyl]-2- methyl- propionate 11a N-but-3-enyl- 38% CH₂Cl₂:MeOH:NH₄OH oil 13f: Ethyl 2-[3-(4- phthalimide 90:9:1 amino-butyl)-phenyl- Rf = 0.27 sulfanyl]-2-methyl- propionate 11b N- 41% CH₂Cl₂:MeOH:NH₄OH oil 13g: Ethyl 2-[4-(2- vinylphthalimide 90:9:1 amino-ethyl)-phenyl- Rf = 0.28 sulfanyl]-2-methyl- propionate 11b N- 38% CH₂Cl₂:MeOH:NH₄OH oil 13h: Ethyl 2-[4-(3- allylphthalimide 90:9:1 amino-propyl)- Rf = 0.23 phenylsulfanyl]-2- methyl- propionate 11e N- 63% CH₂Cl₂:MeOH oil 13i: Tert-butyl 2- vinylphthalimide 90:10 [4-(2-amino-ethyl)- Rf = 0.18 phenylsulfanyl]-2- methyl-propionate TLC: silica gel 60 F 254 Merck

b) Intermediates 13j-13n

The synthesis of intermediates 13j-13n is carried out from the starting bromine compounds listed in table 15 following the procedures described for the synthesis of 13b using variously N-alkylated phthalimides.

TABLE 15 intermediates 13j-13n Starting N-substituted molecule phthalimide Yield TLC State Intermediates 13i-13n

N-allylphthalimide 47% CH₂Cl₂:MeOH:NH₄OH 80:18:2Rf = 0.25 solid 13j: 3-(3-Amino-propyl)-phenol

N-but-3-enylphthalimide 49% CH₂Cl₂:MeOH:NH₄OH 80:18:2Rf = 0.24 oil 13k: 3-(4-Amino-butyl)-phenol

N-allylphthalimide 59% CH₂Cl₂:MeOH:NH₄OH 80:18:2Rf = 0.20 oil 13l: 3-(3-Methoxy-phenyl)-propylamine

N-but-3-enylphthalimide 77% CH₂Cl₂:MeOH:NH₄OH 80:18:2Rf = 0.28 oil 13m: 4-(3-Methoxy-phenyl)-butylamine

N-pent-4-enyl-phthalimide 24% CH₂Cl₂:MeOH:NH₄OH 90:9:1Rf = 0.45 oil 13n: 5-(3-Methoxy-phenyl)-pentylamine TLC: silica gel 60 F 254 Merck

Intermediate 14: a) Ethyl 2-[4-(2-heptylamino-ethyl)-phenoxy]-2-methyl-propionate (14a)

13a (4.1 g, 5 mmol) is placed in the presence of heptanoic acid (2.3 ml, 16.5 mmol) in 42 ml of dichloromethane. 2.3 ml (16.5 mmol) of triethylamine is added followed by 2.8 ml (18.2 mmol) of diethylcyanophosphonate. This mixture is stirred for 24 h at ambient temperature then the reaction medium is dry concentrated. The residue is taken up in H₂O and extracted with ethyl acetate. After drying on MgSO₄, the organic phases are dry concentrated and the oil isolated is purified by flash chromatography on silica (CH₂Cl₂:MeOH 90:10). 4.7 g of oil are obtained (yield=78%). 13 ml of a BH₃/THF solution (1 M) is placed at 0° C. under nitrogen then the oil previously obtained, diluted in 20 ml of THF, is added dropwise. This mixture is placed at reflux for 2 h then neutralized by 10 ml of EtOH/HCl (1.5 N). The solution is again placed at reflux for 1 h then dry concentrated. The residue obtained is taken up in a saturated sodium bicarbonate solution then extracted with dichloromethane. After drying on MgSO₄, the organic phases are dry concentrated and the oil isolated is purified by flash chromatography on silica (CH₂Cl₂:MeOH 90:10). 1.6 g of intermediate 14a is thus isolated in the form of an oil (yield=73%). TLC silica gel 60 F 254 Merck, CH₂Cl₂:MeOH:NH₄OH 90:9:1, Rf=0.50.

b) Intermediates 14b-14c

The synthesis of intermediates 14b-14c is carried out starting from intermediate 13a according to the procedure described for the synthesis of 14a using various carboxylic acids.

TABLE 16 intermediates 14b-14c Carboxylic Total acid yield Eluent Form Intermediates 14b-14c

78% CH₂Cl₂:MeOH90:10Rf = 0.37 oil 14b: Ethyl 2-methyl-2-[4-(2-phenethylamino-ethyl)-phenoxy]-propionate

65% CH₂Cl₂:MeOH90:10Rf = 0.44 oil 14c: Ethyl 2-methyl-2-{4-[2-(3-phenyl-propylamino)-ethyl]-phenoxy}-propionate TLC: silica gel 60 F 254 Merck

EXAMPLES Example 1 Ethyl 2-{2-[2-(4-butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate (1)

Compound 1 is prepared according to synthesis method 1:1 g (4 mmol) of derivative 10g and 1 g (3.8 mmol) of triazine 5a are placed in 3 ml of DMF in the presence of 0.5 g (3.7 mmol) of K₂CO₃. This mixture is stirred at 120° C. for 7 h. After filtration and dry concentration of the reaction medium, the residue obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 98:2). 1.2 g of white crystals are isolated (yield=74%).

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 95:5, Rf=0.40. F=76° C.

RMN ¹H (CDCl₃): 0.94 ppm (t, 3H, J=7.4 Hz), 1.20 ppm (t, 3H, J=7.2 Hz), 1.39 ppm (m, 2H, J=7.5 ppm), 1.63 ppm (m, 8H), 3.16 ppm (t, 0.2H, J=7.6 Hz), 3.50 ppm (s, 3H), 3.95 ppm (t, 2H, J=7.6 Hz), 4.22 ppm (q, 2H, J=7.0 Hz), 4.37 ppm (t, 2H, J=7.6 Hz), 7.00 ppm (m, 4H).

Example 2 Ethyl 2-{3-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate (2)

Compound 2 (oil) is prepared from triazine 4b and from intermediate 10h according to synthesis method 1.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 90:10, Rf=0.62.

Example 3 Ethyl 2-methyl-2-(3-{2-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate (3)

Compound 3 (oil) is prepared from triazine 6a and from intermediate 10h according to synthesis method 1.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 90:10, Rf=0.57.

Example 4 Ethyl 2-methyl-2-(3-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propyl}-phenoxy)-propionate (4)

Compound 4 (oil) is prepared from triazine 4a and from intermediate 12a according to synthesis method 1.

TLC silica gel 60 F 254. Merck, petroleum ether:AcOEt 70:30, Rf=0.30.

Example 5 Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate (5)

Compound 5 (oil) is prepared from triazine 4b and from intermediate 12a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.52.

Example 6 Ethyl 2-methyl-2-(3-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propyl}-phenoxy)-propionate (6)

Compound 6 (oil) is prepared from triazine 6a and from intermediate 12a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.46.

Example 7 Ethyl 2-{3-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate (7)

Compound 7 (oil) is prepared from triazine 7a and from intermediate 12a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.61.

Example 8 Ethyl 2-(3-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propyl}-phenoxy)-2-methyl-propionate (8)

Compound 8 (oil) is prepared from triazine 7b and from intermediate 12a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.53.

Example 9 Ethyl 2-methyl-2-(3-{5-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-propionate (9)

Compound 9 (oil) is prepared from triazine 4a and from intermediate 12b according to synthesis method 1.

TLC silica gel 60 F 254′ Merck, petroleum ether:AcOEt 80:20, Rf=0.34.

Example 10 Ethyl 2-{3-[5-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (10)

Compound 10 (oil) is prepared from triazine 4b and from intermediate 12b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.54.

Example 11 Ethyl 2-{3-[5-(4-butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (11)

Compound 11 (oil) is prepared from triazine 5a and from intermediate 12b according to synthesis method 1.

TLC silica gel 60. F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.29.

Example 12 2-{3-[5-(4-Butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionic Acid (12)

Compound 12 (oil) is prepared by hydrolysis of compound 11 (HCl 12 N, reflux, 16 h, 62%).

TLC silica gel 60 F 254 Merck, CH₂Cl₂:MeOH 90:10, Rf=0.43.

Example 13 Ethyl 2-{3-[5-(2,4-dibutyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (13)

Compound 13 (oil) is prepared from triazine 1c and from intermediate 12b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.63.

Example 14 Ethyl 2-(3-{5-[4-Butyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-2-methyl-propionate (14)

Compound 14 (oil) is prepared from triazine 5b and from intermediate 12b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.35.

Example 15 Ethyl 2-{3-[5-(4-butyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (15)

Compound 15 (oil) is prepared from triazine 5c and from intermediate 12b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.53.

Example 16 Ethyl 2-methyl-2-(3-{5-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-propionate (16)

Compound 16 (oil) is prepared from triazine 6a and from intermediate 12b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.33.

Example 17 Ethyl 2-{3-[5-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (17)

Compound 17 (oil) is prepared from triazine 7a and from intermediate 12b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.36.

Example 18 Ethyl 2-(3-{5-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-2-methyl-propionate (18)

Compound 18 (oil) is prepared from triazine 7b and from intermediate 12b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 70:30, Rf=0.35.

Example 19 Ethyl 2-{3-[5-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (19)

Compound 19 (oil) is prepared from triazine 7c and from intermediate 12b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.51.

Example 20 Ethyl 2-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl)-phenoxy]-2-methyl-propionate (20)

Compound 20 (oil) is prepared from triazine 4b and from intermediate 10f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.28.

Example 21 Ethyl 2-methyl-2-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl]-phenoxy}-propionate (21)

Compound 21 (oil) is prepared from triazine 6a and from intermediate 10f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 60:40, Rf=0.46.

Example 22 Ethyl 2-[4-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl)-phenoxy]-2-methyl-propionate (22)

Compound 22 (oil) is prepared from triazine 7a and from intermediate 10f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.34.

Example 23 Ethyl 2-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl]-phenoxy}-2-methyl-propionate (23)

Compound 23 (oil) is prepared from triazine 7b and from intermediate 10f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 90:10, Rf=0.61.

Example 24 Ethyl 2-methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate (24)

Compound 24 (oil) is prepared from triazine 4a and from intermediate 10j according to synthesis method 1.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 90:10, Rf=0.45.

Example 25 Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate (25)

Compound 25 (oil) is prepared from triazine 4b and from intermediate 10j according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.45.

Example 26 Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate (26)

Compound 26 (oil) is prepared from triazine 7a and from intermediate 10j according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.46.

Example 27 Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate (27)

Compound 27 (oil) is prepared from triazine 4b and from intermediate 12c according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.33.

Example 28 Ethyl 2-methyl-2-(4-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-butyl}-phenoxy)-propionate (28)

Compound 28 (oil) is prepared from triazine 4a and from intermediate 12d according to synthesis method 1.

TLC silica, gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.31.

Example 29 Ethyl 2-{4-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-butyl]-phenoxy}-2-methyl-propionate (29)

Compound 29 (oil) is prepared from triazine 4b and from intermediate 12d according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.49.

Example 30 Ethyl 2-methyl-2-(4-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-butyl}-phenoxy)-propionate (30)

Compound 30 (oil) is prepared from triazine 6a and from intermediate 12d according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether AcOEt 70:30, Rf=0.35.

Example 31 Ethyl 2-(4-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-butyl}-phenoxy)-2-methyl-propionate (31)

Compound 31 (oil) is prepared from triazine 7b′ and from intermediate 12d according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.51.

Example 32 Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenylsulfanyl}-2-methyl-propionate (32)

Compound 32 (oil) is prepared from triazine 4b and from intermediate 12e according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.37.

Example 33 Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propoxy]-phenoxy}-2-methyl-propionate (33)

Compound 33 is prepared according to synthesis method 2: 1.1 g (3.7 mmol) of triazine 9q, 0.83 g (3.7 mmol) of ester 10b and 1.25 g (4.7 mmol) of PPh₃ are placed in 30 ml of THF at 40° C. 0.74 ml (4.7 mmol) of DEAD diluted in 10 ml of THF is added dropwise and the mixture is stirred for 1 h at 40° C. Afterwards, the reaction medium is dry concentrated and the residue obtained is purified by flash chromatography on neutral alumina (heptane:AcOEt 80:20). 0.8 g of compound 33 is isolated in the form of clear oil (yield=43%).

TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.30.

Example 34 Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propoxy]-phenylsulfanyl}-2-methyl-propionate (34)

Compound 34 (oil) is prepared from triazine 9q and from intermediate 11c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.33.

Example 35 Ethyl 2-(3-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propoxy}-phenoxy)-2-methyl-propionate (35)

Compound 35 (oil) is prepared from triazine 9r and from intermediate 10b according to synthesis method 2.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.50.

Example 36 Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-butoxy]-phenoxy}-2-methyl-propionate (36)

Compound 36 (oil) is prepared from triazine 9s and from intermediate 10b according to synthesis method 2.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.34.

Example 37 Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-butoxy]-phenylsulfanyl}-2-methyl-propionate (37)

Compound 37 (oil) is prepared from triazine 9s and from intermediate 11c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.37.

Example 38 Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethoxy]-phenylsulfanyl}-2-methyl-propionate (38)

Compound 38 (oil) is prepared from triazine 9p and from intermediate 11d according to synthesis method 2.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.33.

Example 39 Ethyl 2-(4-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propoxy}-phenoxy)-2-methyl-propionate (39)

Compound 39 (oil) is prepared from triazine 9r and from intermediate 10c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.50.

Example 40 Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethoxy]-phenoxy}-2-methyl-propionate (40)

Compound 40 (oil) is prepared from triazine 9b and from intermediate 10c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.29.

Example 41 Ethyl 2-(4-{2-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethoxy}-phenoxy)-2-methyl-propionate (41)

Compound 41 (oil) is prepared from triazine 9a and from intermediate 10c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.

Example 42 Ethyl 2-{4-[2-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethoxy]-phenoxy}-2-methyl-propionate (42)

Compound 42 (oil) is prepared from triazine 9c and from intermediate 10c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.85.

Example 43 Ethyl 2-(4-{2-[2,4-bis-(3-cyclohexylpropyl)-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethoxy}-phenoxy)-2-methyl-propionate (43)

Compound 43 (oil) is prepared from triazine 9d and from intermediate 10c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 80:20, Rf=0.85.

Example 44 Ethyl 2-methyl-2-(4-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-propionate (44)

Compound 44 (oil) is prepared from triazine 9f and from intermediate 10c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.36.

Example 45 Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenoxy}-2-methyl-propionate (45)

Compound 45 (oil) is prepared from triazine 9g and from intermediate 10c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.48.

Example 46 Ethyl 2-methyl-2-(4-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-propionate (46)

Compound 46 (solid) is prepared from triazine 9h and from intermediate 10c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.37. F=116° C.

Example 47 Ethyl 2-{4-[3-(4-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenoxy}-2-methyl-propionate (47)

Compound 47 (oil) is prepared from triazine 9i and from intermediate 10c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.30.

Example 48 Ethyl 2-(4-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-2-methyl-propionate (48)

Compound 48 (oil) is prepared from triazine 9j and from intermediate 10c according to synthesis method 2.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.

Example 49 Ethyl 2-{4-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenylsulfanyl}-2-methyl-propionate (49)

Compound 49 (oil) is prepared from triazine 9i and from intermediate 11d according to synthesis method 2.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.46.

Example 50 Ethyl 2-{4-[4-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butoxy]-phenoxy}-2-methyl-propionate (50)

Compound 50 (oil) is prepared from triazine 9i and from intermediate 10c according to synthesis method 2.

TLC silica gel 60. F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.

Example 51 Ethyl 2-(3-{3-[(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(4,4,4-trifluoro-butyl)-amino]-propoxy}-phenoxy)-2-methyl-propionate (51)

Compound 51 (oil) is prepared from triazine 9m and from intermediate 10b according to synthesis method 3 using Mitsunobu coupling conditions such as those described for example 33.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 90:10, Rf=0.56.

Example 52 Ethyl 2-(3-{3-[(2,4-Dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-propoxy}-phenylsulfanyl)-2-methyl-propionate (52)

Compound 52 (oil) is prepared from triazine 9n and from intermediate 11c according to synthesis method 3 using coupling conditions such as those described for example 33.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 70:30, Rf=0.22.

Example 53 Ethyl 2-(4-{3-[(2,4-Dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-propoxy}-phenylsulfanyl)-2-methyl-propionate (53)

Compound 53 (oil) is prepared from triazine 9n and from intermediate 11d according to synthesis method 3 using coupling conditions such as those described for example 33.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 80:20, Rf=0.45.

Example 54 Ethyl 2-(3-{4-[(2,4-Dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-butoxy}-phenylsulfanyl)-2-methyl-propionate (54)

Compound 54 (oil) is prepared from triazine 9o and from intermediate 11c according to synthesis method 3 using coupling conditions such as those described for example 33.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 70:30, Rf=0.25.

Example 55 Ethyl 2-(2-{2-[3,5-Dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate (55)

Compound 55 is prepared according to synthesis method 4: 6.6 g (16.1 mmol) of triazine 1d, 2 g (13.4 mmol) of 2 (2-methoxy-phenyl)-ethylamine and 4.7 ml (33.9 mmol) of triethylamine are placed in 20 ml of n-butanol at 120° C. for 28 h. After dry concentration of the reaction medium, the residue obtained is taken up in H₂O and extracted with AcOEt. The organic phases are dried on MgSO₄, then dry concentrated. The oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 90:10). 3.1 g of intermediate are isolated in the form of an oil (yield=48%) which are then placed in 30 ml of CH₂Cl₂ at 0° C. under nitrogen. A solution of BBr₃ (12.8 ml at 1 M in CH₂Cl₂) is added dropwise and the reaction medium is stirred for 3.5 h at ambient temperature. It is then placed at 0° C. and acidified by a 0.1 N HCl solution until pH=1. The organic phase is decanted and then washed with 100 ml of water. After drying on MgSO₄, it is dry concentrated and the residue obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 95:5). 1.9 g of the corresponding phenol is isolated yield=65%) which is then placed in 2 ml of DMF in the presence of 1.9 ml (12.5 mmol) of ethyl bromoisobutyrate and 0.6 g (4.3 mmol) of K₂CO₃. The reaction medium is heated at 130° C. for 22 h then filtered and dry concentrated. The oil obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 98:2). 0.8 g of compound 55 (yield=34%) is isolated in the form of an oil.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 95:5, Rf=0.66.

Example 56 Ethyl 2-methyl-2-(3-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate (56)

Compound 56 is prepared according to synthesis method 1: 1.1 g (4.4 mmol) of derivative 13b and 1 g (3.7 mmol) of triazine 4a are placed in 10 ml of nBuOH in the presence of 1.3 ml (9.3 mmol) of triethylamine. This mixture is stirred at 120° C. for 24 h. After dry concentration of the reaction medium, the residue obtained is taken up in H₂O and extracted with AcOEt. The organic phases are dried on MgSO₄, then dry concentrated. The oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 90:10). 0.4 g of compound 56 is isolated in the form of an oil (yield=27%).

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.19.

Example 57 Ethyl 2-{3-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (57)

Compound 57 (oil) is prepared from triazine 4b and from intermediate 13b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.44.

Example 58 Ethyl 2-methyl-2-(3-{2-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate (58)

Compound 58 (oil) is prepared from triazine 6a and from intermediate 13b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.33.

Example 59 Ethyl 2-{3-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (59)

Compound 59 (oil) is prepared from triazine 7a and from intermediate 13b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.

Example 60 Ethyl 2-(3-{2-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate (60)

Compound 60 (oil) is prepared from triazine 7b and from intermediate 13b according to synthesis method 1.

TLC silica gel 60 F 254. Merck, petroleum ether:AcOEt 90:10, Rf=0.22.

Example 61 Ethyl 2-{3-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionate (61)

Compound 61 (oil) is prepared from triazine 7a and from intermediate 13d according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.61.

Example 62 Ethyl 2-methyl-2-(3-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-propionate (62)

Compound 62 (oil) is prepared from triazine 4a and from intermediate 13j according to synthesis method 4.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 90:10, Rf=0.60.

Example 63 Ethyl 2-(3-{3-[2-(2-cyano-ethyl)-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate (63)

Compound 63 (oil) is prepared from triazine 3a and from intermediate 13j according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.44.

Example 64 Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate (64)

Compound 64 (oil) is prepared from triazine 4b and from intermediate 13j according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.20.

Example 65 Ethyl 2-methyl-2-(3-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-propionate (65).

Compound 65 (oil) is prepared from triazine 6a and from intermediate 13j according to synthesis method 4.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 90:10, Rf=0.78.

Example 66 Ethyl 2-(3-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate (66)

Compound 66 (oil) is prepared from triazine 1d and from intermediate 131 according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.49.

Example 67 Ethyl 2-{3-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate (67)

Compound 67 (oil) is prepared from triazine 7a and from intermediate 13c according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.

Example 68 Ethyl 2-(3-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate (68)

Compound 68 (oil) is prepared from triazine 7b and from intermediate 13j according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.63.

Example 69 Ethyl 2-{3-[3-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate (69)

Compound 69 (oil) is prepared from triazine 1e and from intermediate 13j according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.53.

Example 70 Ethyl 2-{3-[3-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate (70)

Compound 70 (oil) is prepared from triazine 7c and from intermediate 13j according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.47.

Example 71 Ethyl 2-(3-{3-[4-benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate (71)

Compound 71 (oil) is prepared from triazine 8a and from intermediate 13j according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.30.

Example 72 Ethyl 2-{3-[3-(4-Benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate (72)

Compound 72 (oil) is prepared from triazine 8b and from intermediate 13j according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.42.

Example 73 Ethyl 2-{4-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenylsulfanyl}-2-methyl-propionate (73)

Compound 73 (oil) is prepared from triazine 7a and from intermediate 13e according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.58.

Example 74 Ethyl 2-methyl-2-(3-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate (74)

Compound 74 (oil) is prepared from triazine 4a and from intermediate 13m according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.21.

Example 75 Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate (75)

Compound 75 (oil) is prepared from triazine 4b and from intermediate 13m according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.44.

Example 76 Ethyl 2-methyl-2-(3-{4-[4-(3-methyl-but-2-enyl)-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate (76)

Compound 76 (oil) is prepared from triazine 5d and from intermediate 13m according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.

Example 77 Ethyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate (77)

Compound 77 (oil) is prepared from triazine 6a and from intermediate 13k according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.35.

Example 78 Tert-butyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate (78)

Compound 78 (oil) is prepared from triazine 6a and from intermediate 13m according to synthesis method 4 using tert-butyl bromoisobutyrate in the last step.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 60:40, Rf=0.35.

Example 79 2-Methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionic Acid (79)

After the hydrolysis of compound 78 (trifluoroacetic acid/CH₂Cl₂, yield=61%), compound 79 is isolated in the form of a solid.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:MeOH 90:10, Rf=0.73. F=116° C.

Example 80 Ethyl 2-(3-{4-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (80)

Compound 80 (oil) is prepared from triazine 1d and from intermediate 13m according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.32.

Example 81 Ethyl 2-(3-{4-[2-(2-cyano-ethyl)-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (81)

Compound 81 (oil) is prepared from triazine 3b and from intermediate 13k according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.20.

Example 82 Ethyl 2-(3-{4-[2-heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (82)

Compound 82 (oil) is prepared from triazine 6b and from intermediate 13k according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.37.

Example 83 Tert-butyl 2-(3-{4-[2-heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (83)

Compound 83 (oil) is prepared from triazine 6b and from intermediate 13m according to synthesis method 4 using tert-butyl bromoisobutyrate in the last step.

TLC silica gel 60 F 254 Merck, heptane:AcOEt 60:40, Rf=0.43.

Example 84 2-(3-{4-[2-Heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionic Acid (84)

After the hydrolysis of compound 83 (trifluoroacetic acid/CH₂Cl₂, yield=76%), compound 84 is isolated in the form of an oil.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:MeOH 95:5, Rf=0.39.

Example 85 Ethyl 2-(3-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (85)

Compound 85 (oil) is prepared from triazine 7b and from intermediate 13m according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.75.

Example 86 Ethyl 2-(3-{4-[2-(2-cyano-ethyl)-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (86)

Compound 86 (oil) is prepared from triazine 3c and from intermediate 13m according to synthesis method 4.

TLC silica gel 60 F 254. Merck, petroleum ether:AcOEt 70:30, Rf=0.51.

Example 87 Ethyl 4-(6-{4-[3-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-butylamino}-4-heptyl-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-but-2-enonate (87)

Compound 87 (oil) is prepared according to synthesis method 6: 0.2 g (5 mmol) of NaH (60% in paraffin) is placed in suspension in 10 ml of DMF at 0° C. under nitrogen. 1.4 g (2.6 mmol) of compound 86 diluted in 4 ml of DMF is added dropwise. The mixture is stirred for 4.5 h at ambient temperature then dry concentrated. The residue is taken up in H₂O and extracted with AcOEt. The organic phases are dried on MgSO₄, then dry concentrated. The oil obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 90:10) and 0.8 g of solid is isolated (yield=63%). 78 mg (1.9 mmol) of NaH (60% in paraffin) is placed in suspension in 15 ml of DMF at 0° C. under nitrogen. The solid previously isolated (0.8 g, 1.6 mmol) diluted in 5 ml of DMF is added dropwise then this mixture is stirred for 1 h at ambient temperature. 0.29 ml (2.1 mmol) of ethyl 4-bromo-but-2-enoate is added and then stirring is continued for 9 h. After dry concentration, the residue obtained is taken up in H₂O and extracted with AcOEt. The organic phases are dried on MgSO₄, then dry concentrated. The oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 80:20). 0.6 g of compound 87 is isolated in the form of an oil (yield=56%).

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.33.

Example 88 Ethyl 2-{3-[4-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate (88)

Compound 88 (oil) is prepared from triazine 1e and from intermediate 13k according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.53.

Example 89 Ethyl 2-{3-[4-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate (89)

Compound 89 (solid) is prepared from triazine 7c and from intermediate 13k according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.37. F=58° C.

Example 90 Ethyl 2-(3-{3-[4-benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (90)

Compound 90 (oil) is prepared from triazine 8a and from intermediate 13k according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.46.

Example 91 Ethyl 2-{3-[4-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate (91)

Compound 91 (oil) is prepared from triazine 8b and from intermediate 13k according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.60.

Example 92 Ethyl 2-(3-{5-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-pentyl}-phenoxy)-2-methyl-propionate (92)

Compound 92 (oil) is prepared from triazine 1d and from intermediate 13n according to synthesis method 4.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.45.

Example 93 Ethyl 2-methyl-2-(3-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-propionate (93)

Compound 93 (oil) is prepared from triazine 4a and from intermediate 13f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20; Rf=0.45.

Example 94 Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate (94)

Compound 94 (oil) is prepared from triazine 4b and from intermediate 13f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.26.

Example 95 Ethyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl)}-phenylsulfanyl)-propionate (95)

Compound 95 (oil) is prepared from triazine 6a and from intermediate 13f according to synthesis method 1.

TLC silica gel 60 F 2.54 Merck, petroleum ether:AcOEt 80:20, Rf=0.34.

Example 96 2-Methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-propionic Acid (96)

After the hydrolysis of compound 95 (BBr₃/CH₂Cl₂, yield=49%), compound 96 is isolated in the form of a solid.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 80:20, Rf=0.24. F=106° C.

Example 97 Ethyl 2-(3-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-2-methyl-propionate (97)

Compound 97 (oil) is prepared from triazine 7b and from intermediate 13f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.74.

Example 98 Ethyl 2-{3-[4-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate (98)

Compound 98 (oil) is prepared from triazine 1e and from intermediate 13f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.53.

Example 99 Ethyl 2-{3-[4-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate (99)

Compound 99 (oil) is prepared from triazine 7c and from intermediate 13f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.43.

Example 100 Ethyl 2-(3-{4-[4-Benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-2-methyl-propionate (100)

Compound 100 (oil) is prepared from triazine 8a and from intermediate 13f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.27.

Example 101 Ethyl 2-{3-[4-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate (101)

Compound 101 (oil) is prepared from triazine 8b and from intermediate 13f according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.39.

Example 102 Ethyl 2-methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate (102)

Compound 102 (oil) is prepared from triazine 4a and from intermediate 13a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.22.

Example 103 Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (103)

Compound 103 (oil) is prepared from triazine 4b and from intermediate 13a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 90:10, Rf=0.54.

Example 104 Ethyl 4-[6-{2-[4-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-ethylamino}-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-but-2-enoate (104)

Compound 104 (oil) is prepared from triazine 3b and from intermediate 13a according to synthesis method 6 with ethyl 4-bromo-but-2-enoate used in the alkylation step.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.34.

Example 105 Ethyl 2-(4-{2-[2-(3-cyclohexyl-propyl)-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate (105)

Compound 105 (oil) is prepared from triazine 6c and from intermediate 13a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.44.

Example 106 Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (106)

Compound 106 (solid) is prepared from triazine 7a and from intermediate 13a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.60. F=54° C.

Example 107 Ethyl 2-(4-{2-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate (107)

Compound 107 (solid) is prepared from triazine 7b and from intermediate 13a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.47. F=63° C.

Example 108 Ethyl 2-{4-[2-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (108)

Compound 108 (oil) is prepared from triazine 1e and from intermediate 13a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.57.

Example 109 Ethyl 2-{4-[2-(4 benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (109)

Compound 109 (solid) is prepared from triazine 8b and from intermediate 13a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.60. F=65° C.

Example 110 Ethyl 2-{4-[2-(2,4-bis-benzyloxymethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)ethyl]-phenoxy}-2-methyl-propionate (110)

Compound 110 (oil) is prepared from triazine 1g and from intermediate-13a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.34.

Example 111 Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(4,4,4-trifluoro-butyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate (111)

Compound 111 is prepared according to synthesis method 5: 3.2 g (14.7 mmol) of triazine 1b and 5.4 ml (36.8 mmol) of 2-(4-methoxy-phenyl)-ethylamine are placed in 30 ml of nBuOH in the presence of 5.1 ml (36.8 mmol) of triethylamine at 130° C. for 10.5 h. After dry concentration, the residue obtained is taken up in H₂O and extracted with AcOEt. The organic phases are dried on MgSO₄, then dry concentrated. The oil obtained is purified by flash chromatography on silica (heptane:AcOEt 50:50) and 2.3 g of solid is isolated (yield=54%). 0.48 g (12 mmol) of NaH (60% in paraffin) is placed in suspension in 15 ml of DMF at 0° C. under nitrogen. 2.3 g (7.9 mmol) of the previously isolated solid diluted in 5 ml of DMF are added dropwise. The mixture is stirred for 0.5 h at ambient temperature and then 4.7 g (19.8 mmol) of 1,1,1-trifluoro-4-iodo-butane are added and stirring is continued for 6.5 h. After dry concentration, the residue obtained is taken up in H₂O and extracted with AcOEt. The organic phases are dried on MgSO₄, then dry concentrated. The oil obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 95:5) and 0.82 g of oil is isolated (yield=26%). 0.4 g of the latter is then placed in 15 ml of CH₂Cl₂ at −60° C. under nitrogen, a BBr₃ solution (1 M in CH₂Cl) (0.24 ml diluted in 2 ml of CH₂Cl₂) is added dropwise and the reaction medium is stirred for 2 h at ambient temperature It is next placed at 0° C. and neutralized by a 1 N HCl solution. The organic phase is decanted and then washed with 100 ml of water. After drying on MgSO₄, it is dry concentrated and 0.38 g of the corresponding phenol is isolated (quantitative yield). It is then placed in 0.5 ml of ethyl bromoisobutyrate in the presence of 0.14 g (1 mmol) of K₂CO₃ at 150° C. for 5 h. After filtration and dry concentration, the residue obtained is purified by flash chromatography on silica (CH₂Cl₂:AcOEt 95:5) and 0.25 g of compound 111 is isolated in the form of an oil (yield=51%).

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 90:10, Rf=0.65.

Example 112 Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-ethyl}-phenoxy)-2-methyl-propionate (112)

Compound 112 (oil) is prepared from triazine 1b and from intermediate 14a according to synthesis method 1.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 70:30, Rf=0.70.

Example 113 2-(4-{2-[(2,4-Dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-ethyl}-phenoxy)-2-methyl-propionic Acid (113)

Compound 113 is prepared from triazine 1b and from 2-(4-methoxy-phenyl)-ethylamine according to synthesis method 5 by alkylating nitrogen with 1-bromoheptane and by using tert-butyl bromoisobutyrate. After hydrolysis with trifluoroacetic acid in CH₂Cl₂, compound 113 is isolated in the form of oil.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:MeOH 90:10, Rf=0.43.

Example 114 Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-phenethyl-amino]-ethyl}-phenoxy)-2-methyl-propionate (114)

Compound 114 (oil) is prepared from triazine 1b and from intermediate 14b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 90:10, Rf=0.74.

Example 115 Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(3-phenylpropyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate (115)

Compound 115 (oil) is prepared from triazine 1b and from intermediate 14c according to synthesis method 1.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:AcOEt 90:10, Rf=0.63.

Example 116 Ethyl 2-(4-{2-[(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-phenethyl-amino]-ethyl}-phenoxy)-2-methyl-propionate (116)

Compound 116 (oil) is prepared from triazine 7a and from intermediate 14b according to synthesis method 1.

TLC silica gel 60 F 254 Merck, CH₂Cl₂, Rf=0.52.

Example 117 Ethyl 2-(4-{2-[(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(3-phenyl-propyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate (117)

Compound 117 (oil) is prepared from triazine 7a and from intermediate 14c according to synthesis method 1.

TLC silica gel 60 F 254 Merck, CH₂Cl₂, Rf=0.46.

Example 118 2-Methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenylsulfanyl)-propionic Acid (118)

Compound 118 is prepared from triazine 4a and from intermediate 13i according to synthesis method 1. After hydrolysis with trifluoroacetic acid in CH₂Cl₂, compound 118 is isolated in the form of a solid.

TLC silica gel 60 F 254 Merck, AcOEt, Rf=0.42. F=128° C.

Example 119 Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionate (119)

Compound 119 (oil) is prepared from triazine 4b and from intermediate 13g according to synthesis method 1. TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.60.

Example 120 2-{4-[2-(2-Heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionic Acid (120)

Compound 120 is prepared from triazine 4b and from intermediate 13i according to synthesis method 1. After hydrolysis with trifluoroacetic acid in CH₂Cl₂, compound 120 is isolated in the form of a solid.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:MeOH 90:10, Rf=0.34. F=70° C.

Example 121 2-{4-[2-(4-Butyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionic Acid (121)

Compound 121 is prepared from triazine 5c and from intermediate 13i according to synthesis method 1. After hydrolysis with trifluoroacetic acid in CH₂Cl₂, compound 121 is isolated in the form of oil.

TLC silica gel 60 F 254 Merck, CH₂Cl₂:MeOH 98:2, Rf=0.46.

Example 122 Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionate (122)

Compound 122 (solid) is prepared from triazine 7a and from intermediate 13g according to synthesis method 1. TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.67. F=49° C.

Example 123 2-(4-{2-[4-Heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenylsulfanyl)-2-methyl-propionic Acid (123)

Compound 123 is prepared from triazine 7b and from intermediate 13i according to synthesis method 1. After hydrolysis with trifluoroacetic acid in CH₂Cl₂, compound 123 is isolated in the form of a solid.

TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.19. F=86° C.

Example 124 Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)propyl]-phenylsulfanyl}-2-methyl-propionate (124)

Compound 125 (oil) is prepared from triazine 4b and from intermediate 13h according to synthesis method 1. TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.20.

Pharmacological Evaluation

In Vitro

Activation of transcription (transactivation) of the reporter gene controlled by specific response elements after binding of the ligand to the receptor (reporter gene assay).

These experiments were carried out according to J. M. Lehmann et al. (J. Biol. Chem. 1995, 270:12953-12956) with several modifications. Subconfluent Cos-7 cells (ATCC, CRL-1651) were transfected with (i) chimeric receptors containing the binding domain for human PPARα or PPARγ or PPARδ ligand bound to the DNA binding domain of yeast galactosidase (Gal-4), and (ii) the reporter plasmid containing five copies of the Gal-4 response element upstream of the thymidine kinase promoter adjacent to the luciferase gene (p5xUAS-tk-Luc). After 24 hours, these cells were treated for the following 24 hours by compounds and their vehicle and luciferase activity were evaluated after cellular extraction according to the manufacturer's (Promega) recommendations.

The results are reported in table 17 below, in which the designation “hit” indicates a compound whose transactivation level is significant but for which definition of an EC₅₀ is not possible, and in which the designation “nd” indicates that no data was collected.

TABLE 17 reporter gene transactivation by various human PPAR subtypes hPPAR- hPPAR- hPPAR- GAL4 alpha GAL4 gamma GAL4 delta Examples EC₅₀ (μM) EC₅₀ (μM) EC₅₀ (μM) Fenofibric 16.9 65.2 >100 acid Rosiglitazone 0 1.12 0 Pioglitazone >10 4.77 0 1  3-10 0 0 2 >10 ~10 0 3 ~3 0 0 4 >10 0 0 5 ~3 ~10 0 6 ~0.3 0 0 7 0.3-1   1-3  0 8 ~0.3 3-10 0 9 3-10 ~10 0 10 0.3-1   ~1 0 11 0.3-1   1-3  0 12 ~0.03 1-3  hit 13 0.01-0.03 0.1-0.3  ~3 14 0.01-0.03 ~1 ~10 15 0.001-0.003 0.1-0.3  hit 16 ~0.1 3-10 0 17 0.3-1   ~0.3 0 18 0.03-0.1  ~1 0 19 ~3 3-10 0 20 hit hit 0 21  3-10 0 0 22 10 hit 0 23 1 hit 0 24 >10 0 0 25 hit >10 hit 26 >10 0 0 27 ~3 3-10 3-10 28 ~10 hit 0 29  3-10 3-10 3-10 30 0.03-0.1  >10 hit 31 ~0.1 ~1 3-10 32 1-3 hit 0 33 ~3 ~3 0 34 >10 >10 0 35 0.03-0.1  3-10 ~10 36 0.3-1   3-10 hit 37 >10 ~10 0 38 >10 >10 0 39 0.1-0.3 3-10 ~3 40  3-10 ~10 >10 41 ~0.1 ~10 1-3  42 ~1 >10 1-3  43 ~3 hit 0 44 >10 3-10 0 45 1-3 ~3 hit 46 0.3-1   0 0 47 ~0.3 ~0.3 hit 48 0.3-1   0.3-1   ~3 49 >10 >10 0 50 >10 ~10 0 51  3-10 >10 0 52 hit 0 0 53 1-3 0 0 54 >10 0 0 55 >10 0 0 56 hit hit 0 57 ~3 1-3  hit 58 >10 0 0 59 1-3 nd 0 60 >10 hit 0 61 ~3 nd 0 62 >10 0 0 63 0 hit 0 64 >10 3-10 hit 65 0.1-0.3 >10 0 66 0.03-0.1  >10 ~10 67 ~1 nd 0 68 0.1-0.3 3-10 0 69 1-3 ~10 0 70 ~1 ~10 0 71 ~1 hit 0 72  3-10 3-10 0 73 0.1-0.3 nd 0 74 ~1 3-10 0 75  3-10 3-10 0 76 0.01-0.03 1-3  3-10 77 ~0.3 3-10 0 78 >10 0 0 79 ~0.03 3-10 0 80 0.01-0.03 0.3-1   >10 81 0.3-1   >10 0 82 ~0.01 0.1-0.3  hit 83 >10 0 0 84 0.003-0.01  ~0.3 1-3  85 ~0.03 1-3  hit 86 >10 ~1 hit 87 ~0.3 0.1-0.3  hit 88 ~0.3 ~10 0 89 >10 1-3  3-10 90 ~0.1 ~10 0 91 0.3-1   3-10 0 92 0.003-0.01  3-10 0 93 >10 hit 0 94  3-10 3-10 0 95 1-3 >10 0 96 0.03-0.1  ~10 >10 97 1-3 hit 0 98 >10 0 0 99 >10 3-10 0 100 1-3 >10 0 101 1-3 0 0 102 >10 hit 0 104 1-3 >10 0 105 1-3 ~10 0 106 ~1 nd >10 107 ~1 hit 0 108 >10 hit 0 109 ~1 nd 3-10 110 1-3 hit >10 111 0 hit 0 112 1-3 ~10 1-3  113 0.3-1   3-10 0.3-1   114 ~10 nd 0 115 ~3 nd >10 116 ~10 nd 0 117 ~10 nd 0 118 1-3 ~10 0 119 0.3 0.3 hit 120 0.3-1   1-3  hit 121 0.03-0.1  1-3  hit 122 ~0.3 nd >10 123 0.1-0.3 ~10 0 124 0.3-1   >10 0

In Vivo

Normalization of metabolic parameters (cholesterol, plasma triglycerides) in an insulinresistant male rat (Ico: ZUCKER-fa/fa), unfed for 16-18 hours, after treatment by oral route, once per day for four days, with the compounds to be evaluated or their administration vehicle.

These metabolic parameters are measured by spectrophotometry at the beginning and the end of each animal's treatment.

TABLE 18 Normalization of metabolic parameters Plasma Plasma Examples triglycerides cholesterol 11 inactive at 2.5 −25% at 2.5 mg/kg mg/kg −25% at 10 mg/kg −37% at 10 mg/kg 13 inactive at 2.5 −8% at 2.5 mg/kg mg/kg −12% at 10 mg/kg −28% at 10 mg/kg 15 −22% at 2.5 mg/kg −4% at 2.5 mg/kg −63% at 10 mg/kg −8% at 10 mg/kg 16 inactive at 2.5 −14% at 2.5 mg/kg mg/kg −25% at 10 mg/kg −15% at 10 mg/kg 17 −37% at 10 mg/kg active at 10 mg/kg 41 inactive at 10 −28% at 10 mg/kg mg/kg 45 inactive at 10 −16% at 10 mg/kg mg/kg 46 −32% at 10 mg/kg −13% at 10 mg/kg 47 −45% at 10 mg/kg −25% at 10 mg/kg 53 inactive at 10 −7% at 2.5 mg/kg mg/kg −28% at 10 mg/kg 59 −13% at 2.5 mg/kg −37% at 2.5 mg/kg 65 inactive at 2.5 −13% at 2.5 mg/kg mg/kg −23% at 10 mg/kg −13% at 10 mg/kg 66 inactive at 10 −9% at 10 mg/kg mg/kg 67 −23% at 10 mg/kg −14% at 10 mg/kg 68 active at 10 mg/kg −21% at 10 mg/kg 72 inactive at 10 −21% at 10 mg/kg mg/kg 73 inactive at 10 −14% at 10 mg/kg mg/kg 74 inactive at 2.5 −18% at 2.5 mg/kg mg/kg −29% at 10 mg/kg −26% at 10 mg/kg 75 active at 10 −19% at 2.5 mg/kg mg/kg −13% at 10 mg/kg 76 −7% at 10 mg/kg −16% at 2.5 mg/kg −22% at 10 mg/kg 77 active at 10 mg/kg −29% at 2.5 mg/kg −35% at 10 mg/kg 79 −55% at 2.5 mg/kg −32% at 2.5 mg/kg 80 inactive at 10 −16% at 10 mg/kg mg/kg 81 −17% at 10 mg/kg −12% at 10 mg/kg 82 active at 10 mg/kg −13% at 10 mg/kg 84 inactive at 2.5 inactive at 2.5 mg/kg mg/kg −7% at 10 mg/kg −13% at 10 mg/kg 85 active at 10 mg/kg −21% at 10 mg/kg 92 inactive at 10 −18% at 10 mg/kg mg/kg 95 inactive at .10 −18% at 2.5 mg/kg mg/kg −40% at 10 mg/kg 96 −26% at 2.5 mg/kg −28% at 2.5 mg/kg −60% at 10 mg/kg −21% at 10 mg/kg 112 −31% at 10 mg/kg −43% at 10 mg/kg 113 inactive at 2.5 −30% at 2.5 mg/kg mg/kg −40% at 10 mg/kg −26% at 10 mg/kg 119 active at 2.5 −21% at 2.5 mg/kg mg/kg −32% at 10 mg/kg −29% at 10 mg/kg 120 −27% at 2.5 mg/kg −32% at 2.5 mg/kg −73% at 10 mg/kg −33% at 10 mg/kg 121 −24% at 2.5 mg/kg −7% at 2.5 mg/kg 122 −35% at 10 mg/kg −22% at 10 mg/kg 123 −6% at 2.5 mg/kg −8% at 2.5 mg/kg −20% at 10 mg/kg −14% at 10 mg/kg

Thus, the present invention relates to the compounds of formula I previously defined as novel medicines of use in the treatment of diseases requiring PPAR alpha and/or PPAR gamma receptor agonists. These compounds are of use in the prevention and the treatment of diseases such as diabetic dyslipidemia, hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia, hyperglycemia, metabolic syndrome, obesity, atherosclerosis, and in dermatology in pathologies with an inflammatory component or resulting from abnormal cell differentiation as well as in the treatment of diseases such as psoriasis, acne, atopic dermatitis, cutaneous aging and photoaging.

Lastly, the invention relates to pharmaceutical compounds containing as an active ingredient at least one compound of formula I previously defined, preferably in association with a suitable excipient. 

1) 3,5-Dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula I

in which R₁ and R₂ can be identical or different and represent an alkyl or alkenyl radical, linear or branched, at C₁-C₇, an alkyl radical at C₁-C₆ substituted by groups such as trifluoromethyl, cycloalkyl at C₅-C₆, nitrile, alkoxycarbonylvinyl at C₁-C₄, hydroxycarbonylvinyl, alkoxycarbonyl at C₁-C₄, carboxylate, benzyloxy or phenyl (for which the core phenyl is possibly substituted by one or more groups such as alkyl at C₁-C₄, alkoxy at C₁-C₄, nitro, halogen or trifluoromethyl), —YR₃ represents oxygen or NR₃ in which R₃ represents hydrogen, an alkyl or alkenyl radical, linear or branched at C₁-C₇, an alkyl radical at C₁-C₆ substituted by groups such as trifluoromethyl or phenyl (for which the core phenyl is possibly substituted by one or more groups such as alkyl at C₁-C₄, alkoxy at C₁-C₄, nitro, halogen or trifluoromethyl), Z represents an oxygen atom or a carbon atom which can be bound in ortho, meta or para position on the phenyl group of formula I n can range from 0 to 5 when Z=C or from 2 to 4 when Z=O, X represents oxygen or sulfur, R₄, R₅, R₆, R₇ and R₈ represent hydrogen or fluorine, R₉, R₁₀ and R₁₁ represent hydrogen or an alkyl group, linear or branched, at C₁-C₅, as well as additive salts with pharmaceutically acceptable bases and the various enantiomers of compounds having asymmetrical carbons, as well as their mixtures in all proportions, including racemic mixtures in particular. 2) 3,5-Dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula I according to claim 1 in which: R₁ and R₂ represent, independently one from the other, an alkyl or alkenyl radical, linear or branched, at C₁-C₇, an alkyl radical at C₁-C₆ substituted by groups such as trifluoromethyl, cycloalkyl at C₆, nitrile, or phenyl (for which the core phenyl is possibly substituted by one or more groups such as alkyl at C₁-C₄, alkoxy at C₁-C₄, nitro, halogen or trifluoromethyl), YR₃ represents oxygen or NR₃ in which R₃ represents hydrogen, an alkyl or alkenyl radical, linear or branched, at C₁-C₇, an alkyl radical at C₁-C₆ substituted by groups such as trifluoromethyl or phenyl, Z represents an oxygen atom or a carbon atom which can be bound in ortho, meta or para position on the phenyl group of formula I n can range from 0 to 5 when Z=C or from 2 to 4 when Z=O, X represents oxygen or sulfur, R₄, R₅, R₆, R₇ and R₈ represent hydrogen or fluorine, R₉, R₁₀ and R₁₁ represent hydrogen or an alkyl group, linear or branched, at C₁-C₅. 3) 3,5-Dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula I according to one of the claims 1 and 2 in which: R₁ and R₂ represent independently one from the other, an alkyl or alkenyl radical, linear or branched, at C₁-C₇, an alkyl radical at C₁-C₆ substituted by groups such as trifluoromethyl or nitrile, YR₃ represents oxygen or NR₃ in which R₃ represents hydrogen or a linear or branched alkyl radical at C₁-C₇, Z represents a carbon atom which can be bound in ortho, meta or para position on the phenyl group of formula I, n can range from 0 to 5, X represents oxygen or sulfur, R₄, R₅, R₆, R₇ and R₈ represent hydrogen or fluorine, R₉, R₁₀ and R₁₁ represents hydrogen or a linear or branched alkyl group at C₁-C₅, in particular R₉ and R₁₀ represent a methyl group and R₁₁ hydrogen or an ethyl group. 4) 3,5-Dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula I according to one of the claims 1 and 3 in which: R₁ and R₂ represent independently one from the other, an alkyl or alkenyl radical, linear or branched, at C₁-C₇, possibly substituted at the end of the chain by a trifluoromethyl group, YR₃ represents oxygen or NR₃ in which R₃ represents hydrogen or a linear or branched alkyl radical at C₁-C₇, Z represents a carbon atom which can be bound in meta or para position on the phenyl group of formula I, n can range from 1 to 5, X represents oxygen or sulfur, R₄ to R₈ represent hydrogen, R₉ and R₁₀ represent a methyl radical R₁₁ represents hydrogen or an ethyl radical. 5) Compounds of general formula I according to claim 1) wherein they are selected among:
 1. Ethyl 2-{2-[2-(4-butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate
 2. Ethyl 2-{3-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate
 3. Ethyl 2-methyl-2-(3-{2-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate
 4. Ethyl 2-methyl-2-(3-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate
 5. Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate
 6. Ethyl 2-methyl-2-(3-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate
 7. Ethyl 2-{3-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate
 8. Ethyl 2-(3-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propyl}-phenoxy)-2-methyl-propionate
 9. Ethyl 2-methyl-2-(3-{5-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-propionate
 10. Ethyl 2-{3-[5-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate
 11. Ethyl 2-{3-[5-(4-butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate
 12. 2-{3-[5-(4-Butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionic acid
 13. Ethyl 2-{3-[5-(2,4-dibutyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate
 14. Ethyl 2-(3-{5-[4-butyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-2-methyl-propionate
 15. Ethyl 2-{3-[5-(4-butyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate
 16. Ethyl 2-methyl-2-(3-{5-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-propionate
 17. Ethyl 2-{3-[5-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl propionate
 18. Ethyl 2-(3-{5-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-2-methyl-propionate
 19. Ethyl 2-{3-[5-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate
 20. Ethyl-2-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl)-phenoxy]-2-methyl-propionate
 21. Ethyl 2-methyl-2-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl]-phenoxy}-propionate
 22. Ethyl 2-[4-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl)-phenoxy]-2-methyl-propionate
 23. Ethyl 2-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluorobutyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl]-phenoxy}-2-methyl-propionate
 24. Ethyl 2-methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate
 25. Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate
 26. Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate
 27. Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate
 28. Ethyl 2-methyl-2-(4-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate
 29. Ethyl 2-{4-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate
 30. Ethyl 2-methyl-2-(4-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate
 31. Ethyl 2-(4-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-butyl}-phenoxy)-2-methyl-propionate
 32. Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenylsulfanyl}-2-methyl-propionate
 33. Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propoxy]-phenoxy}-2-methyl-propionate
 34. Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propoxy]-phenylsulfanyl}-2-methyl-propionate
 35. Ethyl 2-(3-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propoxy}-phenoxy)-2-methyl-propionate
 36. Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-butoxy]-phenoxy}-2-methyl-propionate
 37. Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-butoxy]-phenylsulfanyl}-2-methyl-propionate
 38. Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethoxy]-phenylsulfanyl}-2-methyl-propionate
 39. Ethyl 2-(4-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluorobutyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propoxy}-phenoxy)-2-methyl-propionate
 40. Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethoxy]-phenoxy}-2-methyl-propionate
 41. Ethyl 2-(4-{2-[3,5-dioxo-2,4-bis-(4,4,4-trifluorobutyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethoxy}-phenoxy)-2-methyl-propionate
 42. Ethyl 2-{4-[2-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethoxy]-phenoxy}-2-methyl-propionate
 43. Ethyl 2-(4-{2-[2,4-bis-(3-cyclohexyl-propyl)-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethoxy}-phenoxy)-2-methyl-propionate
 44. Ethyl 2-methyl-2-(4-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-propionate
 45. Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenoxy}-2-methyl-propionate
 46. Ethyl 2-methyl-2-(4-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-propionate
 47. Ethyl 2-{4-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenoxy}-2-methyl-propionate
 48. Ethyl 2-(4-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-2-methyl-propionate
 49. Ethyl 2-{4-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenylsulfanyl}-2-methyl-propionate
 50. Ethyl 2-{4-[4-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butoxy]-phenoxy}-2-methyl-propionate
 51. Ethyl 2-(3-{3-[(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(4,4,4-trifluoro-butyl)-amino]-propoxy}-phenoxy)-2-methyl-propionate
 52. Ethyl 2-(3-{3-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-propoxy}-phenylsulfanyl)-2-methyl-propionate
 53. Ethyl 2-(4-{3-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-propoxy}-phenylsulfanyl)-2-methyl-propionate
 54. Ethyl 2-(3-{4-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-butoxy}-phenylsulfanyl)-2-methyl-propionate
 55. Ethyl 2-(2-{2-[3,5-dioxo-2,4-bis-(4,4,4-trifluorobutyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate
 56. Ethyl 2-methyl-2-(3-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate
 57. Ethyl 2-{3-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate
 58. Ethyl 2-methyl-2-(3-{2-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate
 59. Ethyl 2-{3-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate
 60. Ethyl 2-(3-{2-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate
 61. Ethyl 2-{3-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionate
 62. Ethyl 2-methyl-2-(3-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate
 63. Ethyl 2-(3-{3-[2-(2-cyano-ethyl)-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate
 64. Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate
 65. Ethyl 2-methyl-2-(3-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate
 66. Ethyl 2-(3-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate
 67. Ethyl 2-{3-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate
 68. Ethyl 2-(3-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate
 69. Ethyl 2-{3-[3-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate
 70. Ethyl 2-{3-[3-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate
 71. Ethyl 2-(3-{3-[4-benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate
 72. Ethyl 2-{3-[3-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate
 73. Ethyl 2-{3-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenylsulfanyl}-2-methyl-propionate
 74. Ethyl 2-methyl-2-(3-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate
 75. Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate
 76. Ethyl 2-methyl-2-(3-{4-[4-(3-methyl-but-2-enyl)-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate
 77. Ethyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate
 78. Tert-butyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate
 79. 2-Methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionic acid
 80. Ethyl 2-(3-{4-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate
 81. Ethyl 2-(3-{4-[2-(2-cyano-ethyl)-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate
 82. Ethyl 2-(3-{4-[2-heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate
 83. Tert-butyl 2-(3-{4-[2-heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate
 84. 2-(3-{4-[2-Heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl)}-phenoxy)-2-methyl-propionic acid
 85. Ethyl 2-(3-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate
 86. Ethyl 2-(3-{4-[2-(2-cyano-ethyl)-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate
 87. Ethyl 4-(6-{4-[3-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-butylamino}-4-heptyl-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-but-2-enonate
 88. Ethyl 2-{3-[4-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate
 89. Ethyl 2-{3-[4-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate
 90. Ethyl 2-(3-{4-[4-benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate
 91. Ethyl 2-{3-[4-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate
 92. Ethyl 2-(3-{5-[3,5-dioxo-2,4-bis-(4,4,4-trifluorobutyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-pentyl}-phenoxy)-2-methyl-propionate
 93. Ethyl 2-methyl-2-(3-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-propionate
 94. Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate
 95. Ethyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-propionate
 96. 2-Methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-propionic acid
 97. Ethyl-2-(3-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-2-methyl-propionate
 98. Ethyl 2-{3-[4-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate
 99. Ethyl 2-{3-[4-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate
 100. Ethyl 2-(3-{4-[4-benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-2-methyl-propionate
 101. Ethyl 2-{3-[4-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate
 102. Ethyl 2-methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate
 103. Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate
 104. Ethyl 4-[6-{2-[4-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-ethylamino}-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-but-2-enoate
 105. Ethyl 2-(4-{2-[2-(3-cyclohexyl-propyl)-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4,5]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate
 106. Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate
 107. Ethyl 2-(4-{2-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate
 108. Ethyl 2-{4-[2-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate
 109. Ethyl 2-{4-[2-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)ethyl]-phenoxy}-2-methyl-propionate.
 110. Ethyl 2-{4-[2-(2,4-bis-benzyloxymethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate
 111. Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(4,4,4-trifluorobutyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate
 112. Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-ethyl}-phenoxy)-2-methyl-propionate
 113. 2-(4-{2-[(2,4-Dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-ethyl}-phenoxy)-2-methyl-propionic acid
 114. Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-phenethyl-amino]-ethyl}-phenoxy)-2-methyl-propionate
 115. Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(3-phenyl-propyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate
 116. Ethyl 2-(4-{2-[(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-phenethyl-amino]-ethyl}-phenoxy)-2-methyl-propionate
 117. Ethyl 2-(4-{2-[(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(3-phenyl-propyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate
 118. 2-Methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenylsulfanyl)-propionic acid
 119. Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)ethyl]-phenylsulfanyl}-2-methyl-propionate
 120. 2-{4-[2-(2-Heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionic acid
 121. 2-{4-[2-(4-Butyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionic acid
 122. Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionate
 123. 2-(4-{2-[4-Heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenylsulfanyl)-2-methyl-propionic acid
 124. Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenylsulfanyl}-2-methyl-propionate 6) Method of preparation of the chemical compounds according to one of the claims 1) to 5) wherein: a derivative of general formula II is condensed

 in which R₁ and R₂ represent the groups as previously described in formula I with a derivative of general formula III

 where YR₃, n, Z, X, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are such as described previously in formula I, notably in the presence of a base such as triethylamine in n-butanol (when Y═N) or potassium carbonate in dimethylformamide (when YR₃═O). 7) Method of preparation according to one of the claims 1) to 5) of the chemical compounds of general formula I in which Z=O wherein: a) a derivative of general formula II is condensed

 in which R₁ and R₂ represent the groups as previously described in formula I with a derivative of general formula IV

 in which R₃Y can be equal to NH or O and n is such as described previously in formula I, notably in the absence of solvent without adding base (in the case where R₃Y═NH) or in the presence of a base such as K₂CO₃ (in the case where R₃Y═O). b) the derivative obtained V is condensed

 with a compound of general formula VI

 where X, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are as described previously in formula I, notably under conditions such as those of the Mitsunobu reaction in the presence of triphenylphosphine and diethylazodicarboxylate in THF. 8) Method of preparation according to one of the claims 1) to 5) of the chemical compounds of general formula I in which Z=O wherein: a) the alcohol function of a derivative of general formula VII is protected

 in which R₁, R₂ and n are such as described previously in formula I by a protection group such as tertbutyldimethylsilane, in particular under conditions such as THF using chlorotertbutyldimethylsilane and imidazole.

b) the nitrogen of compound VIII previously obtained is alkylated by a halogenated derivative R₃Hal in which the Hal group represents a halogen such as Cl, Br or I and R₃ is as described previously in formula I, under operating conditions such as NaH or tBuOK in DMF.

c) the compound IX thus obtained is deprotected under operating conditions such as tetrabutylammonium fluoride in THF. d) the derivative obtained X is condensed

 with a compound of general formula VI

 where X, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are as described previously in formula I, notably under conditions such as those of the Mitsunobu reaction in the presence of triphenylphosphine and diethylazodicarboxylate in THF. 9) Method of preparation of chemical compounds of general formula I according to one of the claims 1) to 5) when Y═N and which Z=C wherein: a) a derivative of general formula II is condensed

 in which R₁ and R₂ represent the groups as previously described in formula I with a derivative of general formula XI

 in which n, R₃, R₄, R₅, R₆, R₇ and R₈ are as described previously in formula I and A can be hydrogen or a methyl group, notably in the presence of a base such as triethylamine in n-butanol. b) after demethylation (if A=Me, under conditions such as BBr₃ in dichloromethane), the phenol function of derivative XII is alkylated

 by a halogenated derivative of general formula XIII (used as a solvent in the presence of a base such as potassium carbonate)

 in which the Hal group represents a halogen such as Cl, Br or I, and R₉, R₁₀ and R₁₁ are as previously described in general formula I. 10) Method of preparation of chemical compounds of general formula I, according to one of the claims 1) to 5) when Y═N and Z=C wherein: a) a derivative of general formula XIV is alkylated

 in which R₁, R₂, R₄, R₅, R₆, R₇, R₈ et n are as described previously in formula I with a derivative of formula R₃Hal in which the Hal group represents a halogen such as Cl, Br or I and R₃ is as described previously in formula I, under operating conditions such as NaH or tBuOK in DMF. b) after demethylation under conditions such as BBr₃ in dichloromethane, the phenol function of the derivative XII thus obtained is alkylated

 by a halogenated derivative of general formula XIII (used as a solvent in the presence of a base such as potassium carbonate)

 in which the Hal group represents a halogen such as Cl, Br or I, and R₉, R₁₀ and R₁₁ are as previously described in general formula I. 11) Method of preparation of the chemical compounds according to one of the claims 1) to 5) wherein: a) a derivative of general formula I is placed

 in which R₁═(CH₂)₂CN and R₂, R₃, n, Z, X, R₄, R₅, 6, R₇, R₈, R₉, R₁₀ and R₁₁ are as described previously in formula I or R₂═(CH₂)₂CN and R₁, R₃, n, Z, X, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are as described previously in formula I under operating conditions such as in the presence of a base NaH in DMF. b) the nitrogen of the triazine of derivative XIVa or XIVb thus obtained is then alkylated

 by a halogenated derivative of general formula R₁Hal in the case of the intermediate XIVa and of general formula R₂Hal in the case of the intermediate XIVb in which the Hal group represents a halogen such as Cl, Br or I and R₁ and R₂ are as described previously in formula I, under operating conditions such as in the presence of NaH or tBuOK in DMF. 12) As novel medicines of use in the treatment of disorders requiring PPAR alpha and/or PPAR gamma receptor agonists, the compounds defined according to one of the claims 1) to 5). 13) As novel medicines of use in the prevention and the treatment of diseases such as diabetic dyslipidemia, hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia, hyperglycemia, metabolic syndrome, obesity and atherosclerosis, the compounds defined according to one of the claims 1) to 5). 14) As novel medicines of use in dermatology in pathologies with an inflammatory component or resulting from abnormal cell differentiation, the compounds defined according to one of the claims 1) to 5). 15) As novel medicines of use in the treatment of diseases such as psoriasis, acne, atopic dermatitis, cutaneous aging and photoaging, the compounds defined according to one of the claims 1) to 5). 16) Pharmaceutical compound wherein it contains as an active ingredient a compound defined according to one of the claims 1) to 5) in association with a suitable excipient. 